




Title of Dissertation:  DEVELOPMENT OF NANOPARTICLE-BASED 
INTRACELLULAR DUAL SENSING AND 
ACTUATION MODALITIES 
 
     Lauren D. Field, Doctor of Philosophy, 2017 
 
Dissertation directed by:  Igor L. Medintz 
     Naval Research Laboratory 
     Ian White 
     Fischell Department of Bioengineering     
 
 The integration of therapeutics with diagnostic agents, or theranostics, is vital for the 
development of novel and effective disease treatments.  To effectively design new and 
efficient theranostic materials, a thorough understanding of the carrier ensemble, the 
interactions within the construct components, and the surrounding environment is required. 
This dissertation focuses on the development of new strategies to produce an effective 
‘toolbox’ of nanoscale theranostics, namely through the use of a central NP scaffold and the 
visualization technique of Förster Resonance Energy Transfer (FRET). The NP scaffold used 
throughout this work, the semiconductor quantum dot (QD), is ideal for visualizing sensing 
modalities due to their high quantum yield (QY), tunable, narrow and symmetric emission 
profiles with broad, far-UV excitation, and resistance to photobleaching - making them 
optimal FRET donors. We first examined the intracellular assembly of QDs to proteins by 
injecting 545 nm emitting QDs, coated with various capping ligands, into cells transfected to 
express mCherry at two distinct intracellular locations: the cytosol and the plasma 
 
 
membrane. We found that the small, zwitterionic capping ligand CL4 and the cytosolically 
located mCherry protein assembled into the most efficient FRET complexes. We used this 
knowledge to design and implement a novel intracellular actuation modality for drug delivery 
that used a 520 nm emitting QD with the carrier maltose binding protein appended to the 
surface and carrying drug or dye conjugated to a maltose analog, -cyclodextrin in the 
binding pocket. Rather than relying on intracellular environmental changes or external 
stimuli to actuate release, the addition of the innocuous sugar maltose to the medium induced 
cargo actuation and could be visualized via FRET. Finally, the same methods were 
implemented to develop a novel pH sensor to report on the extracellular changes that occur in 
tumor development where the physiological pH is lowered dramatically. Using a 464 nm QD 
scaffold conjugated to pH-responsive FITC, we successfully monitored changes in 
extracellular pH and accurately determined unknown pH values. With the work in this thesis, 
we believe we have contributed greatly to the advancement and development NPs for the 
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Chapter 1: Introduction  
 
Theranostics, or the combination of a therapeutic and diagnostic capabilities 
within the same agent, is a burgeoning field of research with numerous potential 
applications as it can combine delivery of medicinal agents with the ability to image the 
localization of the agent in vivo 3. Overcoming the limitations of systemic drug delivery, 
which include the necessity for high doses and the potential for serious secondary side 
effects, is at the forefront of the design and implementation of theranostic agents. Ideally, 
a well-designed theranostic agent will be targeted, controllable and multifunctional to 
achieve the best therapy possible. Several characteristics are desired from such a system 
in vivo: 1) a large accumulation of the delivered theranostic agent in the targeted location 
such as a tumor site, 2) the potential for the material to be delivered with precision to a 
specified intracellular location and overcome intracellular delivery barriers, 3) minimal 
toxicity caused by the carrier itself, 4) controllable release of material in response to 
either an external stimuli or based on the location’s environment and 5) be visualizable 
for real-time monitoring of delivery and treatment 4. Theranostic treatments are most 
desired for use as chemotherapeutic agents, which traditionally requires biopsy of 
cancerous tissue to evaluate status and therapeutic response, which can take hours or even 
days to thoroughly analyze 5. Therefore, the most effective treatment combines a 
therapeutic and diagnostic agent allowing doctors to better monitor every aspect of 
treatment, from drug release kinetics, efficacy, and localization over time.  In order to 
successfully design new and effective theranostic materials, one needs a thorough 
understanding of the carrier ensemble, the interactions within the construct components, 





Inherent in a theranostic system is the ability to visualize either the location or, 
even more specifically, a reaction or process that occurs at the target location. Design of 
these sensing modalities relies on the visualization of first, the system itself and second, a 
change caused by an interaction or cellular process. These types of sensors usually rely 
on fluorescent molecules as the reporting agents, and these can be organic molecules like 
fluorescein isothiocyanate (FITC) or proteins like green fluorescent protein (GFP). For 
example, FITC is widely used for its responsiveness to the pH of the local environment, 
due to its pKa of 6.4, which causes changes in the absorption and emission over the pH 
range of 5 to 9. Chen et al. capitalized on this property to design a ratiometric pH sensor 
for studying mitochondrial pH 6. They conjugated FITC to a non-pH sensitive 
hemicyanine group that acted as both an internal control and a mitochondrial targeting 
agent as it has a lipophilic cationic nature. The sensor showed good localization to the 
mitochondria of MCF-7 cells and produced a visualizable dynamic range between pH 6.5 
and pH 8.5. This is just one example of the ways research groups are attempting to study 
intracellular pH, be that in mitochondria or, more commonly, lysosomal pH change7-9. 
Later in this dissertation we will discuss the lack of current research focusing on 
extracellular pH sensing and our attempt to expand the current field in this regard.  
Comparable to FITC’s inherent responsiveness to pH, fluorescent proteins can be 
genetically engineered to be sensitive to and report on intracellular processes. Toward 
this end, the Hisabouri Group modified a cyan version of GFP, mTurquoise (480 nm 
emission), and a farther blue emitting protein Sirius (425 nm) to respond to a redox 




balance sensed quenching proteins (Oba-Q), they saw a 50% reduction in QY for the 
mTurquoise protein and an almost 70% reduction in the QY of Sirius after addition of the 
oxidizing agent diamide to protein-expressing HeLaS3 cells. They also saw a recovery of 
fluorescence after 30 minutes, producing a multi-use sensor 10. In addition to sensing an 
environmental change, these systems can be designed to report the presence of a target. 
One such system uses two molecular beacons, which are single-stranded stem-loop DNA 
probes usually conjugated to fluorescent molecules, to look for a mutation in the K-ras 
gene common in cancerous cells 11. To more efficiently tether the fluorescent probe 
(either cyan fluorescent protein (CFP) or yellow fluorescent protein (YFP)) to each 
specific beacon, Blackstock and Chen used the HaloTag® labeling system where a 
modified haloalkane dehalogenase is specifically designed to covalently bind to a suicide 
chlorohexane (CH) ligand. When both of the molecular probes are bound to the mutated 
DNA sequence, the cells expressing the genes can be subsequently imaged 12. In order to 
achieve intracellular delivery of this construct the HIV-derived internalization peptide, 
TAT, was employed to ensure their sensor entered the cells sufficiently to label the 
desired DNA sequence, adding another level of complexity to their system. 
While the aforementioned systems certainly contributed to the development of 
intracellular sensors, many of these modalities are limited by their ability to introduce a 
sensor to a desired cellular location and the inherent limitations of many commonly used 
fluorescent molecules. More specifically, these fluorescent molecules are highly 
susceptible to photobleaching, chemical and physical degradation, broad overlapping 
absorption and emission profiles, and have low QYs 13. Consequently, these limitations 




these and similar sensing mechanisms within a theranostic agent can provide multiple 
levels of information about the interaction of the agent within the body and about the 
potential efficacy of the agent as a therapeutic.  
Combining a theranostic agent with a sensing modality is intrinsically 
complicated and has continuously relied on one type of primary scaffold to engineer 
these constructs: nanoparticles (NP) 14-15. NPs are extremely small, ranging in size from a 
few nanometers to less than 100 nm in diameter 16. This size means that they are similar 
in scale to proteins but smaller than cells themselves, allowing for intracellular targeting 
potential. Additionally, they have many qualities that make them ideal scaffolds for 
complex theranostic agents. These include their large surface-area-to-volume ratio, their 
ability to circulate throughout the body and potentially clear through the renal system 
and, more importantly, the possibility for bioconjugation to targeting proteins or peptides 
17-18. Finally, they can facilitate delivery of the therapeutic component of a theranostic 
agent by being ‘loadable’ with a desired drug cargo. As NPs fall broadly into two 
categories, ‘soft’ and ‘hard’, loading can be either within the NP itself as with soft NPs 
(liposomes, polymersomes, or mesoporous silica NPs), or conjugated to the particle 
surface either with soft NPs or hard NPs (iron oxide NPs, quantum dots, upconversion 
NPs) 19-20. Release of the cargo from the NP once the theranostic agent has been delivered 
to the desired location is the final and critical component to designing these systems, and 





Nanoparticle Delivery Modalities 
Delivery of NP cargo can be broadly defined as occurring by one of two actuation 
modalities. The first is passive actuation, which requires no external stimulus but relies 
on the passive efflux of the cargo, either from within the NP core (as from soft or porous 
NPs) or from the NP surface of all NP types. The second method is an active stimulation 
of release that can be achieved either in response to a change in the NP environment (e.g. 
pH change 21, enzymatic cleavage 22, or redox 23) or to an external application of a power 
source (e.g. magnetism 24, light 25-26, or ultrasound 27).  These mechanisms provide a 
Figure 1: Types of NP actuation 
Figure 1: Types of NP actuation. NP-associated cargos can be actuated or released 
by three general mechanisms: passive, active/extracellularly-triggered or 
active/intracellularly-triggered. (Inset) NP drug cargo release mechanisms. Drug 
cargos are released from soft and hard NPs in various ways. Soft NPs can be loaded in 
the NP core or on the surface while hard NPs are primarily loaded on their surface. 
Drug cargo release is indicated with arrows. (Main) Spatiotemporal control of NP 
actuation. Both soft and hard NPs are subject to actuation by all three modalities. The 
primary differen e is the location of the triggering mechanism as indicated with the 




range of temporal control over release, where passive actuation occurs regardless of 
environment and therefore produces the least control. Active triggering utilizing an 
external stimulus inherently provides a high degree of temporal and spatial control over 
cargo release; while actuation caused by intracellular changes can be highly specific to 
the intracellular localization of the theranostic agent, and so also affords control over 
spatial and temporal release. Such actuation modalities will now be discussed 
individually to more clearly define the pros and cons of each method. 
 
Passive Actuation    
 Passive actuation is a simple and elegant method for incorporation of a delivery 
element to a NP complex, and is uncomplicated in design as it only requires the cargo to 
be contained within or absorbed onto the NP surface. Hard NPs typically have only the 
surface area available as space for cargo loading, and rely on transient interactions. One 
of the more popular types of hard nanoparticulate materials are gold NPs (AuNPs), as 
they can be synthesized in a large range of particle sizes 28 and can be made 
biocompatible and inert through the use of a variety of capping ligands 29. Gold is also on 
the FDA’s ‘generally recognized as safe’ or GRAS list 30. Additionally, they can be 
visualized either with fluorescence if the particle is small enough 31 or using methods like 
X-ray ‘computed tomography’ (CT) scanning 32. Conjugation of these particles with low 
molecular weight drugs has been clearly shown to increase the efficacy of the therapy 
over that of the freely delivered agent, verifying this approach 33-35. Doxorubicin (DOX), 
an anthracycline antitumor drug, is a widely studied small molecule that intercalates in 




DOX onto the surface of AuNPs has been studied by many groups and even simplified to 
a self-assembly method that utilizes heavy metal binding proteins (HMBPs) as shown by 
the Park Lab 33. Reduction of the gold ions within the NP surface was accomplished 
using recombinantly-expressed HMBPs (metallothionein and phytochelatin) and 
produced minimally toxic AuNP-HMBPs that could be incubated with DOX and caused a 
subsequent 30% increase in the efficacy of the DOX as compared to freely delivered 
DOX when tested in HeLa cells. In addition to simply allowing for accumulation due to 
increased circulation times, targeting moieties can be appended to the NP surface. One 
such targeting molecule is folic acid (FA), which the Huang Group conjugated onto the 
surface of graphene quantum dots (QDs) that had DOX absorbed onto the QD surface. 
Addition of FA provided specific delivery of the QDs by targeting the commonly over-
expressed folate membrane receptor in cancerous cells and facilitated increased 
endocytosis and long-term DOX delivery. When analyzing the effect of FA on 
internalization and DOX delivery, the addition of FA increased delivery and subsequent 
cytotoxicity by 40 percent preferentially to the cancerous HeLa cells compared to the 
non-cancerous cell lines (A549 and HEK293A) 37. 
In comparison, soft NPs can incorporate the cargo within the particle itself, and 
the release is mainly driven by a concentration gradient of internal vs external cargo 
concentrations. One type of soft NP currently studied can be created from proteins 
themselves, producing what is called a protein nanocage. The Prosperi Group used DOX 
loaded apoferritin nanocages - a protein that interacts with ferritin receptors that are also 
overexpressed on cancerous cell membranes. These protein-DOX complexes internalized 




and subsequently caused higher rates of cellular apoptosis in HeLa cells 38. Other 
biological components can also be used for soft NP construction - namely lipids, which 
make up the bilayer plasma membrane. Functionalized liposomes were produced by Ding 
et al. containing the drug methotrexate (MTX), with a targeting peptide chosen to 
facilitate delivery of the liposomes to CD-40 positive cells. These cells are a cause of 
autoimmune dysfunction and so the group studied the effect of the delivered liposomes 
on the number of CD-40+ cells in autoimmune encephalomyelitis (EAE) mice, showing 
significant improvement in their clinical scores over 18 days 39. Soft NPs are not required 
to be made of biological agents as was shown by our lab in work using liquid crystal NPs 
(LCNPs). These particles were decorated with transferrin to increase their internalization 
and the high photostability of the embedded pyrelene fluorophore afforded photostable 
imaging not achievable with AlexaFluor-transferrin conjugates. Importantly, the particles 
demonstrated an increase in DOX delivery efficacy by ~40 percent as the LNCPs could 
carry DOX within the NP core, and shows promise for the delivery of other hydrophobic 
drug molecules 40.  
These systems rely on the ability for the NP-drug carrier to remain circulating for 
a longer period of time compared to systemically delivered drugs 41-42 or for 
accumulation of the delivery system due to functionalization with targeting elements, 
subsequently permitting for administration of lower doses 43-44. These types of delivery 
systems are currently the only FDA approved NP-drug systems, with the first being a 
liposomal formulation of DOX, called Doxil 45, and most current NP treatments utilizing 
this concept of a small-molecule drug encapsulated in a protective coat like a liposome, 




release could further reduce the systemic side effects compared to these passive delivery 
systems.    
 
Responsive Actuation 
 Compared to passive actuation, responsive actuation requires an external stimulus 
to trigger the release of the cargo. This can be further broken-down into two types of 
stimulation: internally-triggered or externally-triggered. Internally triggered actuation 
relies on a specific change in the environment around the NP carrier caused by the 
localization of the carrier within various compartments of the cell. One of the most 
commonly utilized changes is that which occurs in the endo-lysosomal pathway. As 
vesicles are shuttled through this pathway, the pH in the vesicles lowers from a 
physiological 7.4 to a final pH of around 5 in the lysosomes 47. Acid-responsive NP 
constructs can be produced from soft polymeric NPs that will degrade in the lysosomal 
environment or hard NP that have acid-labile linkages between the NP surface and the 
cargo. One pH-responsive polymer commonly used in this approach is    
Poly(2-(diisopropylamino) ethyl methacrylate (PDPA), which can be formed into carriers 
via a layer-by-layer technique 48. Using this method, the Dong Group increased the 
circulation time of PDPA particles by functionalization with zwitteronic 
polycaroxybetaine (PCB) methacrylate, targeted them with the use of an appended 
arginylglycylaspartic acid (RGD) peptide, and loaded with a therapeutic cargo (DOX). 
The addition of the targeting RGD peptide increased internalization and efficacy of the 
NPs in HepG2 and HeLa cells and the addition of the PCB produced prolonged 




acid-labile linkages like hydrazone bonds has also shown to be efficacious, with Zolata et 
al. appending Trastuzumab-DOX to the surface of superparamagnetic iron oxide NPs 
(SPIONS) and showing the ability to image the construct using magnetic resonance 
imaging (MRI) in addition to tumor targeting in HER2 + breast tumor bearing BALB/c 
mice and subsequent DOX release after particle internalization 50. An alternate internal 
cellular environment that can be exploited is the redox potential within the cytosol, 
commonly achieved through the use of disulfide linkages. Glutathione is present in the 
cytosol at around 10 mM 51 and will normally reduce any available thiol-linkages. One 
very recent study performed by the Hu Lab uses this reactivity to produce responsive 
mesoporous silica NPs (MSNPs) that are loaded with DOX and capped with thiol-linked 
transferrin (Tf) to ensure the DOX encapsulation. The Tf both targets and subsequently 
causes release after the linker is reduced intracellularly in Huh7 cells, and the efficacy of 
the delivery system was reduced with the addition of free Tf that competitively 
internalized, resulting in hindered DOX release 52. In lieu of a response to an 
environmental change, the presence of intrinsically expressed enzymes can also actuate 
release. Tumor cells have a higher number of matrix metalloprotease (MMP) enzymes to 
facilitate tumor metastasis. MMPs allow for migration of malignant cells as they cleave 
extracellular matrix proteins, allowing cells to move more freely in their environment. 
Using MSNPs, the Cai Group targeted DOX to HepG2 cells in vitro and to tumor-sites in 
a murine model in vivo. Specifically, they capped the MSNPs with a cell penetrating 
peptide, a passivating human serum albumin to increase circulation and MMP-2 
cleavable DOX, the combination of which produced an efficacious therapeutic when 




multifunctional NP system produced a high degree of tumor-specific toxicity with 
minimal side effects on normal organs. All of these methods for actuation necessitate the 
internalization to a specific final location for the delivered theranostic system. However, 
this usually requires the addition of secondary targeting molecules like Tf or RGD 
peptides, and consequently reduces the loading capacity of the NP carrier.   
Externally-triggered actuation often relies on the application of an external power 
source, allowing for more cargo loading potential. One commonly used method, 
magnetically-driven actuation, can provided both targeting and actuation upon 
localization. These systems function due to the use of metal oxide NPs (MNP) as the 
active scaffold, producing a theranostic agent via Magnetic Resonance Imaging (MRI) 54-
55. The common small molecule drug, DOX, was again used in a supramolecular, 
multicomponent MNP. PEI-linked β-cyclodextrin (βCD) coated the MNP surface and 
allowed for the βCD to self-assemble with a polycyclic hydrocarbon adamantine (Ad) 
grafted onto polyamidoamine dendrimers producing complex nanocarriers through a 
host- guest interaction and caging DOX molecules within the NP structure 56. Once 
localized, the MNPs were heated using an alternating magnetic field releasing DOX from 
the βCD. This system reduced the quantity of delivered agent required to 1/1000th of that 
required for free DOX in a murine tumor xenograft model.  
Magnetic stimulation necessities the use of a magnetically-responsive element 
within the NP design, whereas light-triggered actuation does not have such requirements. 
Light can facilitate multiple reactions within the stimulated area, including localized 
heating around the NP construct, the generation of reactive oxygen species (ROS), the 




linkers (quinolone, coumarin, o-nitrobenzyl) can be incorporated into delivery systems 
and stimulated using UV light to trigger release via cleavage. O-nitrobenzyl was used by 
Hu et al. within FA- functionalized micelles carrying the camptothecin (CPT) prodrug 57. 
The micelles were crosslinked using pH-reductive acylhydrazone and disulfide bonds, 
which require acidic and reductive environments to further stimulate release after 
initiation with UV light. UV light, however, is a high energy light source that has limited 
tissue penetration in addition to causing unwanted DNA damage to surrounding tissue 58. 
To overcome some of these limitations, a lower-energy near infrared light (NIR) source 
has been utilized, which can be absorbed by both AuNPs and organic polymers. One 
interesting application used single-wall carbon nanotubes (CNTs) that were 
functionalized with chitosan and loaded into a thermally and pH responsive nanogel 59. 
DOX was integrated into the system through a π-π stacking with the incorporated 
chitosan backbone, and on-demand release was facilitated by CNT heating due to 
excitation with NIR (808 nm) wavelengths. These carriers significantly increased 
cytotoxicity in HeLa cells when subjected to NIR irradiation compared to particles 
without irradiation and free DOX. Finally, ultrasound has also proven to be an effective 
extracellular trigger, as it has a greater penetration depth than either light or magnetic 
targeting and, additionally, can exert physical effects on the tissue in addition to the 
theranostic agent. These including pressure variations (push and stress), acoustic fluid 
streaming, cavitation and local hyperthermia 60. Liposomes loaded with both calcein and 
DOX were used by the Shimizu Group, and were functionalized first with aptamers 
(single stranded DNA) chosen to target platelet-derived growth factor receptors present 




thermosensitive polymer. They showed selective targeting of the breast cancer cell line 
MDA-MB-231 and ultrasound-triggered release and subsequent cell death with 
confirmation of release shown by the fluorescence of the calcein 61. All of these 
externally-triggered actuation modalities require for the targeted delivery location to be 
known to reduce secondary effects due to the power source. This can potentially be an 
issue in cases like metastasis, where the known tumor location is not the only place 
cancerous cells are present and would be missed with this type of treatment.  
One currently under-explored method of actuation is that of an active extracellular 
trigger that does not rely on an external application of power. If release of the cargo could 
be caused by the addition of a secondary and inert molecule, a nutrient for instance, then 
release would happen regardless of the construct location either within the body or a 
specific cellular site. One major focus of this dissertation is the design and 
implementation of an actuation modality that accomplishes just this task that is described 
thoroughly in Chapter 4. As a prototypical NP scaffold, all research described herein was 
performed using semiconductor nanocrystals, which are ideal for biological research and 






Semiconductor Nanocrystal Quantum Dots 
 Semiconductor nanocrystals, or quantum dots (QDs), have unique optical and 
electrical properties due entirely to their extremely small (a few nanometers) size. 
Colloidal versions were first synthesized by Louis Brus in the 1980s 62, these particles are 
so small that their radii are within the Bohr radius for their composite material and so 
produce some very 
interesting optical 
properties as they display 
discrete energy levels as a 
single atom would despite 
being composed of 
hundreds of atoms. This 
quantum confinement 
produces a spatial 
enclosure for the electronic 
charge carriers within the 
nanocrystal structure, and 
the minimal band gap 
becomes a varied quantity 
that is dependent on the 
size of the nanocrystal 
structure. They are commonly synthesized from a binary combination of elements, from 
either group III to V or II to VI on the periodic table of elements and are crystalline in 
Figure 2: QD schematic and size-dependent emission 
Figure 2. (A) Schematic and TEM image of a CdSe/ZnS 
QD. (B) Schematic, photograph, and PL emission 
spectra illustrating progressive c lor changes of 
CdSe/ZnS with increasing nanocrystal size.  Adapted 





nature. One of the most common combinations of these elements is the combination of 
Cd (group II) and Se (group VI) to produce a CdSe core QDs using organometallic 
methods of synthesis 63-65. To improve stability and increase the QYs of these 
nanoparticles, they are often coated with a material that has a higher bandgap then the 
core material. When not protected by the outer shell, the inorganic semiconductor is 
prone to reorganizations of atomic positions within the crystalline structure, causing 
formations of electron traps or ‘holes’ that cause a reduction in the optical properties of 
the material itself. Using a capping material with a higher bandgap essentially confines 
the electrons within the cluster by removing the potential for structural reconstructions. In 
the case of CdSe cores, a shell of ZnS is used as it absorbs at a shorter wavelength then 
CdSe and also will protect it from oxidative degradation, increases the biocompatibility 
of the nanoparticles and passivates the core surface (Figure 2A) 13, 63. As the size of these 
QDs is reduced a visualizable ‘blue shift’ in emission occurs by physically controlling the 
energy levels (Figure 2B) 64. Specifically, the CdSe core QDs can be tuned from a range 
of deep red emission to green emission by changing the core size from ~ 200 Å to 20 Å, 
respectively, which is an ideal range for imaging in biological samples. QDs, regardless 
of size, absorb more readily at higher energies (the UV range of wavelengths) and over a 
broad area, which is a-typical for commonly used fluorophores 66. Despite their similar 
absorption spectra, the emission spectra are tunable, narrow and highly symmetric. 
Additionally, they have relatively long excited state lifetimes (10-30 ns) which is in 
marked contrast to most fluorescent molecules that have shorter lifetimes (<4 ns 67) and 
broad, red-tailed emission profiles 68. QDs have high quantum yields of around ~20% 




fluorophores as previously mentioned in the sensing section 69. The optical properties of 
QDs have other benefits in many areas where fluorescent molecules have limitations for 
biological applications. QDs display the aforementioned marked ‘effective’ Stokes shift, 
a red-shift of emission spectra with respect to absorption spectra, have greater resistance 
to physical and chemical degradation compared to organic or biological fluorophores 70, 
and have a large two-photon cross section which provides the ability to use smaller 
energy wavelengths for excitation deeper in tissue samples. One of the paramount 
properties of QDs is their resistance to photobleaching, which allows for longer-term 
visualization of real-time intracellular process that would not be possible for fluorescent 
probes like FITC or GFP 13, 71.  
While ideal optically, there are some limitations for the use of QDs in biological 
samples. First and foremost, they need to be stabilized as a colloid for use in aqueous 
environments as they are synthesized in organic solvents and commonly have tri-octyl-
phosphine/tri-octylphosphine oxide (TOP/TOPO) ligands on their surface after synthesis. 
There are a range of potential stabilization methods that could be used for QD biological 
applications, including the use of amphiphilic polymers, lipids or silica coatings which 
usually increase the overall size of the QDs dramatically, and therefore limiting the 
intracellular application potential72. Alternatively, the native TOP/TOPO ligands can be 
exchanged for more hydrophilic ligands, producing much smaller and colloidally stable 
QDs. One of the seminal papers written by Chan and Nie utilized mercaptoacetic acid to 
both produce stabilized QDs and conjugate proteins to the QD surface73. The mercapto 
group bound to the zinc present in the ZnS shell of the QDs and the hydrophilic 




amine groups to covalently couple proteins to the QD surface. They showed that the 
addition of transferrin produced internalized clusters of QDs in response to receptor-
mediated endocytosis. After this initial success, numerous other groups started 
investigating a wide range of new capping ligands. The Bawendi group specifically 
examined QDs capped with a small capping ligand dihydrolipoic acid (DHLA), where 
they saw little success using EDC reaction chemistry for protein labeling and so designed 
a new self-assembly method to coordinate maltose binding protein (MBP) to the QD 
surface 74. To facilitate this interaction, they inserted a positively charged leucine zipper 
that would associate with the alkyl-COOH capping ligand and produced a much simpler 
method of bioconjugation for QD applications. Numerous capping ligands have been 
subsequently produced that range from small capping ligands that allow for greater 
access to the QD surface but also can cause aggregation in complex biological 
environments to larger, more biocompatible, capping ligands which can contain long 
poly(ethylene glycol) (PEG) chains that increase the hydrodynamic radius of the QD and 
can make protein coordination more difficult 75-76. One very widely used method of 
bioconjugation was developed based off of the chelation of metal ions by multi-histidine 
tags originally used for protein purification through immobilized metal affinity 
chromatography (IMAC). Proteins engineered to contain His-tags can be associated to the 
QD surface either through the addition of a nitrilotriacetic acid (NTA) into the QD 
capping ligand and assembling with nickel added to the solution or, more simply, by 
allowing the histidine tag to associate with the zinc in the QD protective shell 1, 77-78. 
While this area of research has grown dramatically, further study of the effect these 




required. In Chapter 2 this dissertation examines a range of these capping ligands and 
their effect on intracellular assembly to attempt to increase the potential applications for 
future theranostic research.  
One final concern for biological applications for QDs is that some of the metals 
that make up the most commonly used QDs are toxic (cadmium and lead) and will likely 
never be approved for clinical applications in human subjects, but this does not detract 
from their power as a research tool. There are QD types that use alternate core 
compositions including: ZnO 79, ZnSe:Mn/ZnO 80, InP/ZnS 81. A recent related study 
performed by the Prasad Group on rhesus macaques used lipid-micelle-encapsulated 
cadmium-based QDs intravenously injected and monitored the animals response to the 
injection over 3 months 82. They saw no detrimental effects from the cadmium QD 
delivery, which is very likely due to the passive nature of the micelle coating on the QD 
surface which could have promoted clearance of the QDs from the body. A 2016 meta-
analysis performed by members in our lab analyzed over 307 publications containing 
over 1700 sample data points, each with 24 descriptions, and determined that QD toxicity 
was dependent on their surface properties, the size of the QDs delivered, and the 
exposure time to the QD sample 83. Biological applications of QDs must clearly take 
these factors into account during the design of any potential research system.  
QDs have been used for many studies on the efficacy of NP delivery platforms as 
their optical properties allow for easy monitoring after delivery. Chen et al. used 
glutathione (GSH)-coated CdTe QDs that were conjugated to DOX through a 
condensation reaction and further decorated with FA-terminated PEG to specifically 




moiety facilitated localization of the particles and subsequent increased intracellular 
accumulation of the QD-drug conjugates. The photophysical properties of QDs also mean 
that they make ideal Förster Resonance Energy Transfer (FRET) donors (a more detailed 
discussion of the characteristics of FRET itself will follow after this section) 85-86. Using 
QDs as a biosensor can be accomplished by conjugating them to proteins with an 
attached fluorophore and incorporating certain biological interactions, which can modify 
the distance between the QD and protein and therefore modify the FRET between them 
78. FRET-based QD systems have been used in various applications, including work 
performed by the Bao Group using QDs coupled to pH sensitive fluorescent proteins to 
monitor intracellular pH and determine if modifications to the fluorescent protein, 
mOrange, could allow for a more sensitive system87. In another study, Shaheen et al. used 
plasmid DNA (pDNA) coated QDs as a FRET donor and rhodamine-labeled cations as a 
FRET acceptor to visualize condensation of pDNA within the nucleus to determine an 
effective cationic carrier for increased transfection efficiency 88. These systems show the 
versatility of using QDs as a scaffold for a FRET sensing construct, but more information 
is required to fully understand the tools needed to optimize a QD-based FRET sensor for 
biological applications. One major goal in current nanobiotechnology research is control 
over the location of delivered NPs, be that intracellularly or to a specific site within the 
body. As such, a system that could both deliver a therapeutic while simultaneously 
imaging and sensing could help overcome some current therapeutic limitations and 
provide a basis for designing better, next generation materials. Implementing such a 
system, however, requires both rational design and a practical understanding of the 




Förster Resonance Energy Transfer 
FRET is a mechanism of energy transfer that occurs between a donor (D) 
fluorophore in an excited state and a ground state acceptor (A) fluorophore via 
nonradiative dipole-dipole coupling 65. Due to the inverse 6th power dependency of FRET 
on donor-acceptor separation, close proximity, typically between 20-60Å, of the two 
fluorophores is a requirement for efficient transmission to occur. Additionally, an 
efficiently designed FRET pair should have a high degree of spectral overlap between the 
acceptor emission profile and donor absorbance profile. The following equation depicts 
the calculation used to determine the distance between the donor and acceptor where the 
efficiency of transfer would be 50%, also known as the Förster distance or R0 for the 
donor-acceptor pair: 
 
𝑅0 = 9.78 × 10




This calculation takes into account the refractive index of the medium (𝑛 =1.33), the 
dipole orientation (κ2 = 2/3 for random orientation), the known quantum yield of the 
donor species (QD) and J(λ), the spectral overlap function, which is calculated using the 
following equation: 
  
𝐽(𝜆)  =  ∫  𝐹𝐷(𝜆) 𝜀𝐴(𝜆)𝜆
4 dλ 
 
Where λ is the wavelength of the donor-acceptor spectral overlap, FD( λ) is the integrated 






acceptor at the defined wavelength. The FRET pair chosen, therefore, must take into 
account these factors to produce a system sensitive over the desired physical distance. 
Efficiency for a given system can be calculated by measuring the donors peak 
spectral intensity both in the presence of the acceptor and alone. These values can then be 
used in the following equation to determine the FRET efficiency for the donor-acceptor 
pair in their current state: 





This is a useful equation as it means that efficiency and, therefore, the distance between 
the donor and acceptor can be determined by monitoring the fluorescent output from the 
donor alone.  Once this value is known for the experimental system, the actual distance 
between the donor and acceptor in the current conformational shape can be calculated, 
which is very important given the aforementioned 6th power dependency of efficiency on 
distance 13. Using the calculated FRET efficiency (E) and the calculated R0 the following 
equation can be used: 
 












In Eq. 4, ‘n’ refers to the number of acceptors per donor, and so the effect of increasing 
acceptors on efficiency can also be calculated for the donor-acceptor system. The 






the measured system, and so the distances calculated from these equations is not the 
distance of the acceptor from the surface of the donor, but from the center of the donor. 
To specifically calculate the rDA the efficiency must be determined using Eq. 3, and then 
using the specific R0 for the donor-acceptor pair and the number of acceptors per donor 
(n)- Eq 4 can be utilized to solve for the specific distance between the donor and acceptor 
at that point in time. Given that FRET is highly influenced by the distance between two 
fluorophores, it is a sensitive technique that can allow for investigation of many 
biological processes. These can include protein conformational changes 89, protein 
interactions 90, binding events and therefore kinetic rates for various enzymes and 
metabolic pathways 91-92. 
 The benefit of using QDs as FRET donors are numerous. Specifically, their highly 
tunable emission profiles mean that they can be optimized for a desired acceptor 
molecule, and their excitation far in the UV reduces acceptor direct excitation that can 
influence efficiency calculations. Their large QY’s mean that the effective R0, or the 
distance where FRET efficiency is 50%, for the donor-acceptor pair will be larger, and so 
the dynamic range of the designed FRET pair will be visualizable over longer distances. 
Moreover, the nanometer size range of the QDs allows for a large surface area-to-volume 
ratio and so numerous acceptors can be complexed to the QD surface, increasing the 
efficiency as shown by Eq. 4. The subsequent FRET efficiency can be ‘tuned’ for 
optimum cargo capacity and to produce a more sensitive intracellular sensor than a 
simple one donor - one acceptor system common when using fluorescent probes. Finally, 
it has also been shown that the use of QDs as the donor molecule in a sensing structure 




due to the fact that the excitation of the QD is far in the UV, which reduces direct 
excitation of the acceptor molecule in addition to the nonradiative nature of FRET, so the 
energy being absorbed by the acceptor molecule is significantly less than what would be 
required to visualize the acceptor directly. These benefits have been repeatedly confirmed 






















This dissertation focuses on expanding our understanding of the NP components 
necessary to design an efficient cellular sensor and ultimately a theranostic platform, 
from the type of surface necessary for intracellular use to the efficacy of a new actuation 
modality. Using QDs as the NP platform for visualization, three NP based sensing 
functions were examined to increase the available tool-box for future specialized sensing 
functions.  
 
Specific Aim 1: Understanding the effect of NP surface ligands and protein localization 
on intracellular assembly and FRET efficiency  
The ability of an intracellularly-assembled FRET based construct is examined for 
dependence on the biocompatible capping ligand used on the QD surface and on the 
localization of the targeted protein with the cellular environment. To achieve this, a 
variety of capping ligands were synthesized to vary in size and charge and exchanged to 
populate the QD surface. These QDs were then microinjected into the cytosol of cells that 




were previously transfected to express a hexahistidine-tagged mCherry protein construct. 
The histidine tag allows for the mCherry to self-assemble to the QD surface via metal-
affinity coordination. mCherry is an ideally suited FRET-acceptor for the 545 nm QD 
donor, as they have a high degree of spectral overlap and so a signal would only be 
produced when the protein is coordinated with the QD surface and highly proximal. To 
determine the effect of protein location on the coordination abilities of the injected QD 
and mCherry, a cytosolically expressed mCherry was compared to a trans-membrane 
bound mCherry protein (Figure 3). We expect that the capping ligand will affect the 
intracellular stability of the QDs themselves in addition to the efficiency of the assembled 
FRET construct, and that the location of the mCherry within the cell will also affect the 
efficiency of the construct with the more sterically hindered transmembrane-appended 
mCherry producing a lower FRET efficiency.  
 
Specific Aim 2: Design and implementation of a novel actuation method for cellular drug 
delivery 
The ability of an injected QD-based actuation system to respond to an external 
secondary signal and release cargo was studied. A novel actuation modality was 
produced to respond to an external delivery of an inert secondary nutrient molecule, 
maltose, and to report the release via change in the FRET signal visualized throughout 
the system. The system was analyzed for responsiveness over both time and maltose 
concentration, and for multiple types of cargo. A central scaffold of 520 nm emitting QDs 
was used and had the bacterial periplasmic transport protein, maltose binding protein 




cyclodextrin, a maltose analog, was conjugated to one of two cargos, allowing for them 
to be carried within the MBP’s binding pocket (Figure 4). The cargos were chosen to 
specifically act as acceptors for the 520 QD to produce visual and quantifiable evidence 
of release. The Cy3 analog, TideFluor3 (TF3), was used as a standard acceptor molecule 
and the small molecule drug, DOX, was chosen as a drug analog. TF3 will produce a 
visualizable acceptor peak when within the MBP’s binding pocket but as the DOX has a 
low molar extinction coefficient, the release of the DOX from the binding pocket will be 
measured by monitoring the QD PL peak height. We expect that the release of these 
cargos will be actuated by the addition of maltose and that this process will be affected by 
the time of incubation and the amount of maltose introduced into the cellular 
environment.  
 
Specific Aim 3: Design and implementation of an extracellular pH sensor  
Commonly used pH sensors focus on the intracellular environment, and disregard 
the direct extracellular environment. This area is of particular interest due to the change 




that occurs in tumor microenvironments, where the pH lowers from a physiological level 
of ~7.4 to as low as 5 95. An extracellular pH-sensor was designed utilizing the pH 
responsive FITC fluorescent molecule as a FRET acceptor, and a new biologically-
compatible blue-emitting (462 nm) QD that is an ideal FRET donor for FITC. (Figure 5). 
We anticipate that by avoiding direct excitation of the FITC, the extracellular pH will be 
able to be monitored by looking at the QD and FITC peak emissions. To append the 
sensor system onto the exofacial leaflet of the cells, a novel peptide JB858 was used. This 
peptide was previously found to robustly label the cellular membrane and to remain 
localized for up to 48 hours after delivery. Using this system, we analyzed the 
responsiveness of the QD-FITC pair to various extracellular pH’s ranging from 3 to 8, 
both in the presence and absence of cells and then attempted to discern the pH of various 
‘unknown’ buffers based on the sensor output. We hypothesize that the responsiveness of 
the system will be modified by the more complicated cellular environment but that the 
change will still be discerned over the system’s dynamic range.  
 





Chapter 2: Understanding the Effect of NP Surface Ligands and Protein 
Localization on Intracellular Assembly and FRET Efficiency96  
 
Introduction 
Increasing the efficacy of theranostic probes, those that can simultaneously 
sense/report on as well as treat a disease state, is currently a major focus of biomedical 
research 97-98. In order to effectively design new and even more efficient theranostic 
materials, one needs a thorough understanding of the complex intracellular processes that 
are to be targeted. Historically, fluorescence-based approaches have been used to probe 
and monitor these processes, which necessitates efficient means of delivering/localizing 
the fluorophore to the targeted molecule of interest. Various approaches have been 
employed here and these have ranged from the cellular delivery of fluorophore 
conjugates directed to epitope tags expressed on targeted proteins to the recombinant 
expression of the fluorophore tag as a fusion to the protein of interest. Examples of the 
former include the metal-affinity-driven complexation of nitrilotriacetic acid (NTA)-dye 
conjugates to targeted proteins bearing cognate polyhistidine sequences 99-100. Fessenden, 
for example, used a Cy3-NTA conjugate to probe a dual polyhistidine/green fluorescent 
protein (GFP)-tagged version of the Ca2+ release channel, ryanodine receptor type 1, as a 
means to probe membrane channel function 101. Recombinant tagging of targeted proteins 
for sensing function has also been shown by Yip et al. who expressed the channel protein 
aquaporin as a fusion to the photoconvertible fluorescent protein (mEos2) for the 




utilized the in situ assembly of the sensing construct. One example is the HaloTag system 
wherein a modified haloalkane dehalogenase is specifically designed to exogenously bind 
specified tags that can be linked via a chloroalkane linker to numerous target molecules. 
Los et al. utilized this system to study NF-κB associated cellular processes ranging from 
DNA-protein complexes to protein translocation 103. Another example is the 
FlAsH/ReAsH system developed by Tsien’s group which utilize biarsenical fluorophores 
that react with vicinal tetracysteine motifs expressed in target proteins 104. A still further 
example described by Lee et al. used a fluorescent molecular beacon reporter construct 
comprising a masking/quenching protein, a mitochondrial targeting sequence, a protease-
specific cleavage sequence and a GFP reporter 105. This sensing construct reported on 
both the location and activity level of matrix metalloproteases in living cells. 
Despite the demonstrated utility of the aforementioned sensing schemes, they all 
rely on the use of organic dye fluorophores or fluorescent proteins which can be limited 
by their inherent photophysical properties. Chief among these are their susceptibility to 
photobleaching, potential for chemical degradation, and their limited two photon action 
cross sections which can severely limit deep tissue in vivo imaging applications 13. 
Luminescent semiconductor nanocrystals, or quantum dots (QDs), are nanoscale probes 
whose optical properties are ideal for the real-time, long-term monitoring of cellular 
processes. These attributes include high quantum yields, large ‘effective’ Stokes shift, 
and resistance to photobleaching and chemical degradation 70. Further, their broad 
absorption that extends into the UV coupled with their narrow, size-tunable emission 
peaks make them ideal donors for Förster resonance energy transfer (FRET) 85-86. Finally, 




assembly of biologicals around the central QD. To realize their full utility as the basis of 
intracellular FRET-based sensing (and ultimately in theranostics) one must not only 
develop a full understanding of how to control the FRET process in the sensing assembly 
but one must also be able to exert fine control over the intracellular location of the 
assembled FRET ensemble.   
We have previously shown the ability to drive the intracellular assembly of a 
His6-tagged form of the fluorescent protein mCherry to the Ni
2+-loaded carboxyl termini 
on the polymer shell of a commercial QD preparation 93. Intracellular assembly of such 
FRET-based probes could reduce the complexity of the design and implementation of 
such structures. By having the cells themselves produce components, namely the acceptor 
protein, the location of the final complexes could be controlled without using other 
targeting moieties and, additionally, reactive moieties could be engineered into the 
protein structure and produced via the cells themselves. Using microinjection of QDs 
coupled with the transient expression of His6-mCherry, our results showed the ability to 
assemble in situ a QD-fluorescent protein FRET-based assembly in the cytosol of COS-1 
cells. The assembled complexes were stable intracellularly over a 6 h window and it was 
shown that the QD-sensitized mCherry exhibited an enhanced photostability when 
excited in a FRET configuration using the QD as donor compared to when the mCherry 
was excited directly. Despite these positive findings, numerous aspects of the FRET 
system are worthy of further interrogation in order to fully understand the potential utility 
of such a system for in real-time intracellular sensing. First, the use of a commercial, 
polymer-coated QD preparation in that initial experiment did not allow for strict control 




Second, control over the intracellular localization of the sensor system was not 
implemented, with the complexes only being assembled within the cytosol; any effects of 
intracellular assembly location on the FRET efficiency of the complex were not assessed. 
Here we build upon those initial studies and continue developing this intracellular 
assembly approach by performing a detailed examination of the role played by both the 
QD ligand coating and the assembly location of the QD-mCherry complex on the FRET 
efficiency of the system. Our working hypothesis in this study is that the nature of the 
QD ligand coating as well as the location of the FRET assembly can have a profound 
influence on the resulting FRET efficiency of the system. We make a comparative 
assessment of the FRET efficiency mediated by a suite of custom ligand molecules when 
appended to the surface of our in house-synthesized QDs and examine the effects of 
cytosolic versus membrane-directed assembly of the FRET complex. We discuss our 
results within the context of the considerations that one needs to be mindful of when 





Bovine fibronectin, Anotop-10 filters (0.2 µm) and Dulbecco’s phosphate 
buffered saline (DPBS, 137 mM NaCl, 10 mM phosphate, 3 mM KCl, pH 7.4) were 
purchased from Life Technologies (Carlsbad, CA). Nalgene syringe filters (0.2 μm) were 
purchased from Thermo Scientific. The plasmid encoding cytosolic mCherry utilized was 




plasma membrane was generated by cloning the mCherry gene downstream of the 
extracellular and transmembrane domains of CD1b (CD1b-TMD) 106. The CD1b-TMD-
mCherry-His6 construct was synthesized (Genscript Corp., Piscataway, NJ) and cloned 
into the pcDNA3.1-myc-his(A) vector (Life Technologies) as a KpnI-NotI fragment and 
confirmed by sequencing.  This construct resulted in the expression of a C-terminal His6 
motif to drive QD-mCherry assembly at the membrane. See Supplementary Information 
96 (SI) for the complete nucleic acid and amino acid sequences. Recombinant mCherry-
His6 for QD assembly experiments outside cells was expressed and purified as described 
in ref 93. 
 
QD Synthesis and Capping Ligands 
Core-shell CdSe-ZnS QDs were synthesized to have an emission maxima 
centered at 545 nm and were made hydrophilic by exchange of the native hydrophobic 
trioctylphosphine/trioctylphosphine oxide (TOP/TOPO) ligands with polyethylene glycol 
(MW 750; PEG750)-appended dihydrolipoic acid (DHLA-PEG750-OMe) ligands 
terminated in methoxy groups as previously described 69. For comparison, QDs were also 
capped with either DHLA-PEG600 terminated with nitrilotriacetic acid (DHLA-PEG600-
NTA) or with zwitterionic CL4 capping ligands 107. In a previous report, DHLA-PEG-
NTA ligands were generated “on-QD’ using carbodiimide chemistry after the initial cap 
exchange that removed the native hydrophobic ligands 108. In this study, the DHLA-
PEG600-NTA ligand was first synthesized “off-QD” and then used in the cap exchange 
procedure (see SI for ligand synthesis details 96). TEM analysis showed that QDs capped 




with DHLA-PEG750-OMe had and average diameter of 4.7 ± 0.4 nm (see SI). TEM 
analysis was performed using Gatan Microscopy software to determine the size of at least 
100 randomly selected QDs and averaged to determine the estimated size and 
polydispersity of the QD sizes109. 
 
Cell Culture and Transfection  
African green monkey kidney (COS-1) cells were cultured in complete growth 
medium (Dulbecco’s Modified Eagle’s Medium (DMEM; American Type Culture 
Collection ATCC)) supplemented with 10% (v/v) heat inactivated fetal bovine serum 
(ATCC) and 1% (v/v) antibiotic/antimycotic (Sigma). Cultures were maintained in T25 
flasks and incubated at 37oC under a 5% CO2 humidified atmosphere and passaged at 
80% confluency. For microinjection, cells were seeded at a density of ~6 × 104 cells/mL 
per dish onto MatTekTM 14 mm dishes (Ashland, MA) which were coated overnight with 
fibronectin and allowed to adhere overnight. Transfection of adhered cells was performed 
by removing the complete growth media and washing the cell monolayers once with 
serum free DMEM. During this time, plasmid DNA was complexed with 
Lipofectamine2000TM in serum free DMEM. For each dish, 0.4 μg of DNA was added to 
25 μL of serum free DMEM and allowed to equilibrate while 1 µL of 
Lipofectamine2000TM was mixed carefully with 25 μL of DMEM. After five minutes, the 
two mixtures were combined and allowed to form DNA-lipid complexes for 20 minutes 
at room temperature whereupon 50 μL was added to each well. After a 6 h incubation of 




was removed and replaced with complete media and the cells were cultured overnight to 
allow for mCherry expression.   
 
Microinjection 
After successful transfection was visualized via mCherry fluorescent signal, cells 
were injected using an Eppendorf FemtoJet® Microinjector controlled by an InjectMan® 
NI 2 micromanipulator in a manner similar to that described previously 109. Cells were 
washed once with DPBS to remove excess media and injection was performed on cells 
incubated in filter-sterilized DPBS. The microinjection tip (Eppendorf Femtotips) was 
loaded with 10 μL of QDs (0.2 μm filtered). QDs capped with DHLA-PEG750-OMe and 
CL4 were filtered using DPBS alone while QDs capped with DHLA-PEG600-NTA were 
complexed with ~20 equivalents of NiCl2 for 20 minutes and then filtered with 0.5% FBS 
in DPBS to increase intracellular stability of the QDs upon injection. Injection time and 
pressure was optimized for each tip loading to ensure cellular viability upon injection and 
uniform distribution of QDs throughout the cytosol. Typical injection conditions used 
were 0.6 sec at pressures of 600-700 hPa. 
 
Microscopy and Image Analysis 
Differential interference contrast (DIC) and epifluorescence microscopy were 
utilized to determine the QD distribution thought the cells and visualize the FRET 
interaction between the injected QDs and the expressed mCherry protein. Images were 
acquired with an Olympus IX-71 total internal reflection fluorescence microscope 




lamp and images were collected using the excitation and emission settings described in 
the SI 96. Various fields were examined for mCherry expression and injection was 
performed such that fields of view were comprised of cells containing 1) QD donor only, 
2) mCherry acceptor only and 3) both QD donor and mCherry acceptor.  This approach 
provided the necessary controls for FRET-based image analysis. After injection, fields 
were imaged for the donor excitation and emission (410 nm and 435 nm, respectively), 
acceptor excitation and emission (576 nm and 620 nm, respectively) and donor excitation 
with acceptor emission (410 nm and 620 nm, respectively) in addition to DIC images. 
Relative quantification of relative acceptor sensitization across ligand species was 
performed by first performing a background correction of all images followed by 
normalization of the intensity of the FRET channel to the ligand that mediated the most 
efficient FRET (CL4 in all cases). All data analyses were performed using Image J (ver. 
1.48v). The images were false-colored and prepared for publication using MetaMorph 
Advanced software (ver. 7.8.0.0). 
 
Gel Electrophoresis 
Gel electrophoresis (1% low EEO agarose (Sigma) was performed on DHLA-
PEG600-NTA and CL4 QDs assembled with mCherry protein to demonstrate ratiometric 
assembly. QDs (7.5 pmol) were complexed with increasing ratios of mCherry protein in 
DPBS at QD-mCherry ratios ranging from 1:1 to 1:30 and allowed to incubate for 30 
minutes. Additionally, an mCherry only control was included at the 1:30 mCherry 
equivalent. QD-protein mixtures were subjected to electrophoresis for 30 minutes and 






 To determine the FRET efficiency of the QD-mCherry complexes, QDs were 
assembled with mCherry protein at QD-mCherry ratios from 1:1 to 1:30 and were 
allowed to incubate for 30 minutes.  Control solutions containing mCherry alone were 
included at all mCherry equivalents to determine the contribution of direct excitation of 
the acceptor in absence of the donor. The assemblies were excited at 400 nm using a 
Tecan Infinite M1000 microplate reader and emission spectra was collected from 450-
700 nm. The FRET efficiency at each QD-mCherry ratio was determined using the Eq. 3. 
where FDA and FD are the fluorescence intensity of the QD donor in the presence and 
absence of the mCherry acceptor, respectively. The QD-mCherry separation (r) distance 
for each ratio was determined using the results of the efficiency calculation and according 
to Eq. 4, where R0 is the calculated Förster distance for the donor-acceptor pair. Data 






Experimental Rational and Design  
The design and implementation of a QD-protein FRET ensemble as an effective 
intracellular sensing modality first requires the careful consideration of two critical 
elements: (1) the FRET efficiency of the assembly wherein the donor-acceptor distance 
can be manipulated and (2) control over the intracellular localization of the sensing 
Figure 6: Fluorescent materials and FRET rationale used in this study. 
Figure 6. Fluorescent materials and FRET rationale used in this study. 
(A) Schematic of CdSe-ZnS core-shell QDs and various capping ligands. (B) 
Absorbance and emission spectra of the QD and mCherry (mC) donor-acceptor pair 
showing significant overlap of the QD emission and mCherry absorption, allowing for 
FRET-sensitized emission of mCherry. (C) Intracellular QD-mCherry assembly 
strategies. mCherry was expressed either free in the cytosol or as a fusion to the C-
terminus of the transmembrane receptor, CD1b. Upon microinjection of QDs, a His6 
motif on the C-terminus of the mCherry drove the intracellular assembly of mCherry to 




assembly. Our goal in this study was to assess the ability to control the intracellular 
FRET efficiency of a QD-mCherry donor-acceptor assembly by modulating the ligand 
coating on the QD donor while simultaneously site-specifically expressing the mCherry 
acceptor to control the location of the in situ assembled QD-mCherry complex (cytosol 
versus the cytofacial leaflet of the plasma membrane). We began these studies by first 
performing QD-mCherry assembly and FRET efficiency experiments outside the cellular 
environment. We subsequently employed microinjection of the QD donor coupled with 
transient transfection/expression of the mCherry acceptor to determine the efficiency of 
site-specific intracellular FRET.    
The ligands used in this study included: (1) CL4, a small zwitterionic molecule 
bearing two carboxyl groups and one each secondary and tertiary amine moieties (length 
= ~1.8 nm) 107, (2) DHLA-PEG750-OME (PEG750-OMe; length = ~6.8 nm) 
107, a 
PEGylated ligand terminating with a neutral methoxy group, and (3) DHLA-PEG600-
NTA (PEG600-NTA; length = ~6 nm) 
108, a shorter PEGylated ligand that terminates with 
a negatively charged nitrilotriacetic acid (NTA) function (Figure 6A). All three ligands 
share the same DHLA anchor wherein the thiol pair mediates stable binding of the ligand 
to the ZnS shell. This panel of ligands was selected specifically because they have been 
shown to mediate intracellular QD stability 107 and they span a range of lengths for 
controlling the donor-acceptor distance in the FRET assembly. It is worth noting that the 
CL4 and DHLA-PEG750-OME ligands allow for His-based assembly of the mCherry to 
the ZnS shell (albeit with differing degrees of accessibility of the His6 tag to the Zn 
surface given the varied lengths of the two-ligand species). In contrast, the PEG600-NTA 




moiety. As shown in Figure 6B, FRET in this system is driven by the significant degree 
of spectral overlap between the emission of the 545 nm QD donor and the absorbance of 
the mCherry acceptor. Two further features drive efficient FRET in this QD-protein 
system: (1) the excitation of the QDs in the UV (~350 nm) resulting in negligible direct 
excitation of the fluorescent protein acceptor and (2) the ability to array multiple 
mCherry protein acceptors around the central QD scaffold which enhances overall FRET 
efficiency 110. Finally, the site-specific assembly of the QD-mCherry FRET ensemble 
was controlled by expressing the mCherry acceptor in either of two forms; free in the 
cytosol or appended to the inner leaflet of the plasma membrane via its expression as a 
fusion to the extracellular and transmembrane domains of CD1b (see SI 96). Upon 
injection of the QDs into the cytosol, the free C-terminal His6 domain on either mCherry 













Efficacy of the FRET System 
We first performed in vitro assembly experiments to ensure that the His6-tagged 
mCherry could successfully assemble to the QD surface. Here, increasing ratios of 
mCherry were complexed with the CL4- and PEG600-NTA-capped QDs and the 
complexes were subjected to gel electrophoresis. As shown in Figure 7A, QDs bearing 
either ligand species showed a decreased migration within the gel as increasing numbers 
of mCherry were added, demonstrating an increase in the size of the QD-mCherry 
complexes. Analysis of the PEG750-OMe QDs was not performed here as they have no 
net charge and would not migrate when subjected to electrophoresis. Interestingly, 
Figure 7: Assembly and FRET analysis of the QD-mCherry donor-acceptor pair 
Figure 7. Assembly and FRET analysis of the QD-mCherry donor-acceptor pair. 
(A) 545 nm-emitting QDs capped with CL4 or PEG600-NTA were assembled with 
increasing ratios of mCherry and separated on 1% agarose gels. (B) Emission spectra of 
CL4 capped 550 nm QDs showing sensitization of QD donor emission with increasing 
ratio of mCherry acceptor. Data has been corrected for direct excitation of mCherry. (C) 
Plot of QD-mCherry FRET efficiency as a function of increasing QD-mCherry ratio. 
Line is fit to Eq. 4 by using the calculated rDA values for each ratio and back-calculating 
what the corresponding FRET efficiency should be for that ratio of QD donor to 




assembly of mCherry to the PEG600-NTA QDs resulted in discrete gel bands at nearly all 
QD-mCherry ratios while assembly of the protein to CL4-capped QDs yielded a 
“smearing” banding pattern at ratios below ~10 indicative of a mixed population of QDs 
wherein the number of proteins per QD, or valence, varied. This has been observed 
previously and been consistent with a Poissonian distribution at lower QD-protein 
valencies 76. At valences greater than ~10, however, we observed tight, discrete 
fluorescent bands for QDs capped with both ligands demonstrating the formation of more 
homogeneous populations of QD-mCherry complexes. These results are not unexpected 
given the fact that the manner in which the His6-tagged mCherry assembles to the QD 
surface differs slightly between these two QD species. For the PEG600-NTA QDs, the 
NTA groups on the termini of the PEG600-NTA are more readily accessible to the His6 
tag on the mCherry while for the CL4-capped QDs, the binding of the His6 tag to the Zn-
rich surface of the QD shell requires the interdigitation of the tag through the ligand layer 
to reach the QD shell. Despite this slight difference, our results clearly show that at 
mCherry valences >10, similar binding/assembly efficiencies are obtained for both QDs.  
Having demonstrated the controlled assembly of QD-mCherry complexes, we 
next performed FRET analysis to determine the efficiency of the energy transfer process 
between the QD donor and the mCherry acceptor. For this analysis, we opted to use QDs 
capped with CL4, the shortest ligand used in these studies and, therefore, the species 
expected to mediate the most efficient FRET. To determine the FRET efficiency of the 
QD-mCherry FRET pair, increasing ratios of mCherry were assembled onto the QD 
surface and the emission spectra of the complexes were read when excited at 400 nm. As 




decrease in QD emission coupled with a corresponding increase in mCherry emission 
was observed (Figure 7B). As shown in Figure 7C, a plot of the FRET efficiency (see 
Experimental) versus the QD-mCherry ratio initially follows a linear increase that 
corresponds to the sum of the efficiencies of the aforementioned Poissonian distribution 
of mCherry per QD, as the number of uncoordinated QDs decreased (i.e. QDs with no 
mCherry coordinated to the surface), the FRET efficiency reaches a plateau that 
corresponds to the maximum potential transfer possible for the donor-acceptor pair based 
on both maximum loading capacity and quantum yield of the QD donor. For the CL4 
capped QDs a maximum FRET efficiency of ~50% was achieved when ~20 mCherry 
proteins per QD were assembled onto the QD surface. This corresponded to a calculated 
center-to-center QD-mCherry distance of ~8.1 nm (using an R0 value of 6.5 nm for the 
FRET pair). This calculated distance agrees well with the known sizes of both the QDs 
(~3 nm radius) and of mCherry (~3 nm radius from barrel end to protein center) when 
one factors in the CL4 ligand spacing and the enhanced FRET efficiency driven by the 
arraying of multiple mCherry acceptors around the QD core. Further, these results agree 
well with our previous characterization of the packing of mCherry to the surface of QDs 
of this size 85, 111. Using mathematical modeling that accounted for the QD surface by 
calculating the surface area of a 5.8 nm sphere (545 nm QD diameter ~2.9 nm) and 
estimating the fitting cross section for the maximum mCherry protein per QD, a single 
quantum dot should be able to carry 20 ± 4 mCherry proteins111. Additionally, the other 
two capping ligands were analyzed and found to have maximum FRET efficiencies of 
61% for the PEG600-NTA QDs and 38% for the PEG750-OMe QDs (see SI
96). We 




QDs in organic solution have an extremely high quantum yield (> 90%) but when cap-
exchanged their QY’s decrease to around 20% 69. This reduction is thought to be caused 
in part by the interference of the capping ligand on the available surface states of the 
outer shell. Additionally, the capping exchange process in itself can cause defects in the 
QD surface, which has previously been discussed as a major impetus for high QYs 112-113. 
As the capping ligands and the exchange process damage is not identical for each QD 





Intracellular QD-mCherry Assembly and FRET Efficiency 
 Having confirmed the successful controlled assembly of His6-tagged mCherry to 
the QD donor surface and determined the FRET efficiency of the resultant ensembles, we 
next sought to characterize the intracellular FRET efficiency as a function of both the QD 
ligand coating and the location of the donor-acceptor complex. To achieve this, COS-1 
cells were transiently transfected to express His6-mCherry either free in the cytosol or 
appended to the inner leaflet of the plasma membrane as a fusion to the cell surface 
Figure 8: Cytosolic assembly of QDs and mCherry. 
Figure 8. Cytosolic assembly of QDs and mCherry.  COS-1 cells expressing His6-
terminated cytosolic mCherry proteins were microinjected with QDs coated with CL4, 
PEG600-NTA and PEG750-OMe. Fields were specifically imaged where cells contained 
mCherry only (red arrow), QDs only (blue arrow) or both QD and mCherry (yellow 
arrow) to allow for the appropriate FRET imaging controls. Note the level of efficient 
FRET present in cells injected with the CL4 QDs, with slightly less efficient FRET 
observed in cells injected with PEG600-NTA QDs. PEG750-OMe QDs appeared to 





receptor CD1b. During these studies, we noted that the transfection efficiency across 
experiments was typically ~60-70%. Cells were then injected with QDs capped with 
CL4, PEG600-NTA or PEG750-OMe ligands. We employed an injection strategy that 
ensured all the necessary controls were present in a single field of view. Specifically, the 
injection was executed such that each field of view contained cells with QD donor only 
(no mCherry acceptor), mCherry acceptor only (no QD donor) or both the QD and 
mCherry acceptor. We then imaged these fields for the direct excitation/emission of the 
donor and acceptor and the FRET between the QD and mCherry. In this manner, the 
contribution of the QD donor emission and direct mCherry acceptor emission in the 
FRET channel could be accounted for in the ensuing image analysis. 
As shown in Figure 8, both the injected QDs and the cytosolically expressed 
mCherry displayed a diffuse fluorescence pattern with each fluorophore being well 
distributed throughout the entire cell volume. Interestingly, quantitative analysis of the 
FRET channel showed clear differences in the ligand-specific FRET efficiency. 
Specifically, the cells injected with the CL4-coated QDs displayed the most efficient 
FRET as evidenced by the highest fluorescence intensity in the FRET channel for this 
ligand compared to the PEG600-NTA and PEG750-OMe. Relative quantification of the 
fluorescence intensities in the FRET channel revealed that for the CL4 ligand the QD-
mCherry FRET sensitization was ~7-fold greater than PEG600-NTA and ~5-fold greater 
than PEG750-OMe (see SI 
96). Clearly the shorter, compact CL4 ligand (~1.8 nm in 
length) afforded the more robust assembly of the His6-mCherry protein to the QD surface 




 We then expressed mCherry on the inner leaflet of the plasma membrane as a 
fusion to CD1b and confirmed its localization at the membrane by immunofluorescence 
analysis (SI). Here, slightly different FRET results were obtained when QDs bearing the 
various ligands under study were injected (Figure 9). First, it was apparent that the 
overall fluorescence intensity of the mCherry (under direct excitation) was reduced ~5-
fold compared to when it was expressed freely in the cytosol (see SI). We attributed this 
lower direct fluorescence emission from the mCherry to the fact that the protein was 
expressed within the secretory pathway and processed/directed to the membrane which 
Figure 9: Assembly of QDs and mCherry at the cytofacial leaflet of the plasma membrane. 
Figure 9. Assembly of QDs and mCherry at the cytofacial leaflet of the plasma 
membrane.  COS-1 cells expressing mCherry proteins on the cytofacial leaflet of the 
plasma membrane (as a fusion to CD1b) were microinjected with QDs coated with CL4, 
PEG600-NTA and PEG750-OMe. Imaging was performed as described for Figure 8. Note 
the lower level of mCherry expression due to its localization at the plasma membrane. 
The FRET signal for the CL4 QDs bound to membrane expressed mCherry was ~50% 





resulted in an overall lower level of intracellular mCherry.  It was also clear that the 
efficiency of QD-mCherry FRET was diminished as a result of the mCherry being 
expressed appended the inner leaflet of the membrane. Upon direct comparison, the 
FRET for CL4-capped QDs with membrane-bound mCherry was ~60% that observed for 
this same donor-acceptor pair in the cytosol (see SI). Further, the FRET from for the 
PEG600-NTA QDs was also markedly reduced and there was no measurable FRET signal 
at the plasma membrane for QDs capped with PEG750-OMe. While the lower level of 
mCherry expression likely contributed to this, it is also likely that steric hindrance of the 
mCherry tethered to the inner leaflet played a role in diminishing the ability of the 
injected QDs to dock onto the terminal His6 tag. In this instance, it was only the small 
CL4 ligand-capped QDs that were able to engage in efficient FRET with membrane-
bound mCherry. Taken together with the cytosolic mCherry results, these findings clearly 
demonstrate that not only can the localized expression of the mCherry acceptor mediate 
the controlled site-specific assembly of QD-fluorescent protein but also the nature of the 
capping ligand plays a critical role in the efficiency of FRET once the resulting donor-
acceptor complex is formed.  
 
Discussion 
Our need to understand how to exert fine control over nanomaterials when 
interfaced with cells continues to grow at an almost unabated pace 20, 114. New 
nanoparticle formulations and delivery modalities necessitate that one have a detailed 
working knowledge of how to control the delivery, assembly and intracellular fate of 




sensing platforms, particularly those that employ FRET as the readout modality. Multiple 
factors need to be taken into account including: 1) the facile generation of the FRET 
donor-acceptor assembly, 2) the delivery of the ensemble sensor, and 3) the efficacy of 
the sensor in vitro. Our goal in this study was to perform a detailed characterization of the 
efficiency of the intracellular assembly of a QD-fluorescent protein FRET pair. 
Specifically, we were interested in the role played by the capping ligand on the QD 
surface in modulating the FRET efficiency in the assembly as well as the ability to site-
specifically control the intracellular generation of the FRET complex.  
In previous work, we showed the ability to use metal affinity coordination to drive 
the intracellular in situ assembly of microinjected commercial polymer-coated QDs with 
His6-tagged mCherry protein transiently expressed in the cytosol 
93. Despite the positive 
results obtained in that work, much more remains to be understood in how to control such 
assemblies intracellularly if they are to be used as the foundation of FRET-based sensing. 
For example, the proprietary nature of the polymer capping ligand present on the 
commercially available QDs used in our previous work did not allow for discrete control 
of the distance between the QD donor and protein acceptor. Additionally, no strategy was 
employed to direct the assembly of the FRET complex to a particular subcellular 
location. Building on the initial success of those studies, our goal here was to perform a 
more detailed, controlled analysis of the role played by both the QD donor material itself 
as well as the cellular location of QD-protein assembly. Using the same transient 
expression/injection approach we first systematically tested a suite of QD-capping 
ligands for their ability to assemble to and engage in FRET with mCherry proteins 




longer PEGylated ligand showed the ability to mediate assembly of His6-tagged mCherry 
proteins in a quantitative manner. The CL4 ligand facilitated a maximal FRET efficiency 
of ~50% when ~20 mCherry proteins were arrayed around the central QD. When tested 
intracellularly, this same CL4 ligand mediated the most efficient rate of FRET of the 
ligands tested, a testament to the facile and stable assembly of the His6 tag to the Zn shell 
on the QD donor. Interestingly, we noted distinct differences in the FRET efficiency 
depending on whether the mCherry acceptor was expressed in the cytosol or appended to 
the inner leaflet of the plasma membrane, which tells us that the specific location of the 
final complex directly affects the coordination potential of the intracellular assembly. 
This should be taken into account for the future design and implementation of such 
systems, as the sensitivity of the FRET constructs will vary depending on the potential 
maximum FRET efficiency.  
A few salient features of this system bear pointing out. First, the intracellular 
synthesis of the acceptor portion of the FRET ensemble is at the same time elegant and 
practical; it obviates the need for assembly of the preformed FRET ensemble outside the 
cell followed by its subsequent cellular delivery and targeting. Second, the intracellular 
location of the assembled complex was controlled entirely by manipulating the location 
of the His6-bearing protein acceptor. The success of this approach opens the exciting 
possibility of other means of directing the site-specific, acceptor-driven QD-protein 
assembly process. For example, instead of expression of as a fusion with a 
transmembrane receptor, the inclusion of a post-translational modification signal (e.g., 
palmitoylation 115 or farnesylation 116 signal sequence) or a nuclear localization signal 117 




of the genetically-encoded mCherry acceptor allows for the modification of the spacer 
sequence between the His6 tag and the mCherry protein. Here, the inclusion of 
recognition sequences for kinases, proteases or other enzymes can realize the sensing 
modalities for a variety of cellular processes. It is fundamental studies such as those 
performed herein that are a critical first step in building the appropriate “toolbox” that 
will ultimately drive the successful implementation of these QD-based FRET sensors that 
utilize intracellularly expressed fluorescent proteins as energy acceptors for the sensing 






Chapter 3: Design and Implementation of a Novel Actuation Method for 
Cellular Drug Delivery 
 
Introduction 
Systemic delivery, the most commonly available drug delivery method available 
on the market, requires large repeated doses to effectively treat many diseases and it can 
have serious secondary side effects 118. The reduction of these secondary side effects, in 
addition to reduced dosages, is at the forefront of the development of new drug delivery 
methods. One critical area of research is the development of theranostic agents which 
combine both a therapeutic and a diagnostic moiety to allow for simultaneous delivery 
and visualization of the release of the therapeutic agent 3. Development of these 
theranostic agents requires that numerous criteria be met. First, the agent itself must be 
non-toxic and biocompatible. Second, it must have long circulation time coupled with the 
ability to be cleared from the bloodstream. Finally, the agent must efficiently carry and 
deliver therapeutic cargo with fidelity and control. Cumulatively, achieving these 
properties within the context of a single deliverable agent is a considerable challenge.  
One area of research that is attempting to overcome these obstacles is the design 
of nanoparticle (NP)-mediated drug delivery complexes 14-15. NPs are on the appropriate 
size scale for delivery of materials to cells; they are larger than proteins but much smaller 
than cells and possess a large surface area-to-volume ratio. NPs can be complexed with 
targeting agents like proteins or peptides, carry drug or imaging cargo and release them 
via a variety of actuation methods. The inherent fluorescence properties of some NPs 
allows for easy tracking while other NPs must be conjugated to fluorescent molecules for 




by which the drug cargo is released or “actuated”. As discussed in the Introduction, 
various NP actuation modalities have been realized to include, for example, the passive 
efflux of drug cargos from the surface or core of a variety of NPs 38. Other forms of NP 
actuation are active and take advantage of either inherent cellular processes or states (e.g., 
pH 21 or enzymatic activity 22) or rely on the use of hardwired devices such as lasers 25-26 
to actively trigger cargo release from the NP. One of the inherent limitations of light-
triggered actuation is its limited tissue depth penetration (often only tens to hundreds of 
microns) which necessitates the development of non-light-based methodologies for active 
cargo release 119. An ideal active NP actuation system would combine the exquisite 
control of time-resolved cargo release with a simple yet effective triggering mechanism 
to affect the release of the drug cargo.  
Here, we have designed a prototypical NP actuation bioconjugate that 
incorporates many of the desired attributes of active actuation in a simple, modular, and 
tractable platform. Importantly, rather than light stimulation, drug release is mediated by 
the addition of a competitive structural analog to the extracellular medium. The system 
uses a central QD as the NP scaffold upon which is self-assembled a multicomponent 
drug delivery complex. The central QD scaffold possesses a multitude of properties that 
are ideal for controlled drug delivery, as enumerated in the Introduction. Briefly, they are 
bioconjugatable via histidine-tag coordination, they have impressive optical properties for 
long-term intracellular monitoring and make ideal FRET donors for distance-dependent 
measurements. See Chapter 5 for more discussion of histidine-tag coordination. The full 
ensemble conjugate consists of the QD decorated with multiple copies of the bacterial 




pocket is complexed the cycolamylose betacyclodextrin (βCD) which exists as a 
conjugate to either a dye tracer, TideFluor3 (TF3), or the cancer chemotherapeutic, 
doxorubicin (DOX). Once introduced to into cells, the TF3- or DOX-βCD is displaced 
from the ensemble in a time- and dose-dependent manner by the addition of maltose to 
the extracellular environment. This conjugate system is a novel means by which to 
achieve the active actuation of NP-appended drug cargos and represents a new pathway 




Anotop-10 filters (0.2 µm) and Dulbecco’s phosphate buffered saline (DPBS) 
were purchased from Life Technologies (Carlsbad, CA). Hanks buffered saline solution 
(HBSS) was made to specifically contain no glucose: 137 mM NaCl, 5.4 mM KCl, 0.3 
mM Na2HPO4, 0.4 mM KH2PO4, 4.2 mM NaHCO3, 1.3 mM CaCl2, 0.5 mM MgCl2, 0.4 
mM MgSO4.   
 
Synthesis of QDs and β-cyclodextrin (βCD) Conjugation  
Semiconductor nanocrystals or quantum dots (QDs) were synthesized as 
previously discussed previously and rendered hydrophilic via cap exchange 69. Briefly, 
core-shell CdSe/ZnS QDs were synthesized to have emission maxima centered around 
520 nm, or purchased with emission maxima centered around 655nm (Invitrogen), and 
had their native hydrophobic trioctylphosphine/trioctylphosphine oxide (TOP/TOPO) 




that the 520 nm QDs had an average diameter of 4.6 ± 0.4 nm. The TideFluor3WS was 
conjugated to the βCD as previously reported in 120 and purified as described in 121.The 
DOX conjugated βCD was custom synthesized by BioSynthesis (Lewisville, TX). In 
brief, βCD was monotosylated by reaction with tosyl chloride, then treated by 
ethylenediamine to afford amine-functionalized βCD (H2N-βCD). Meanwhile, 
doxorubicin was treated by disuccinimidyl suberate (DSS) to yield succinimidyl-
activated DOX. Finally, the H2N-βCD and DSS-DOX were reacted to produce βCD-
DOX conjugate, which was purified by reverse phase HPLC and characterized by 
MALDI-TOF MS (purity >95%). Schematic of final product shown in appendix (Figure 
A1). 
 
Maltose Binding Protein Synthesis 
Maltose binding protein (MBP) was purified from Escherichia coli strain 
BL21(De3) (New England Biolabs Ipswich, MA) harboring a pET22 MBP construct that 
facilitated the incorporation of a C-terminal hexahistidine tag. Briefly, 5 mL of Terrific 
Broth (TB) medium containing 100 µg/mL of ampicillin was inoculated with a single 
colony from a Lysogeny Broth (LB) Agar plate containing ampicillin. The culture was 
incubated for 16 hours at 37°C. The entire culture then served as the inoculum for a 500 
mL volume of TB containing ampicillin. The culture was incubated at 37°C with shaking 
in a 2 L baffled flask for approximately 3 hours, until mid-log stage was reached. Protein 
expression was induced at mid-log phase with the addition of Isopropyl-ß-D-
thiogalactopyranoside (IPTG) to a final concentration of 0.5 mM. The incubation 




hours. The culture was transferred to a 500 mL centrifuge bottle. Cells were pelleted at 
4000 x g for 30 minutes at 4°C. The supernatant was discarded and the pellet frozen at -
80°C for 3 hours to improve cell lysis efficiency. The frozen pellet was resuspended in 30 
mL of lysis buffer (1/2x PBS, 1 mM EDTA, 0.1% Triton X-100, 1mg/mL lysozyme) then 
transferred to a 50 mL conical tube. The cell suspension was immobilized on a rocker 
platform and incubated at room temperature for 30 minutes with gentle agitation to allow 
for the degradation of the peptidoglycan and bacterial membranes. The suspension was 
then sonicated 6 times while on ice using a Branon Sonifer 450 (80% duty cycle, output 
control 5). The lysate was transferred to 50 mL conical tubes and centrifuged at 4500 x g 
for 30 minutes to pellet insoluble material. Following centrifugation, the supernatant was 
decanted to a new 50 mL conical tube. A 1 mL bead volume of HisPur Nickel_NTA resin 
(ThermoFisher) was added to the clarified material. The his-tagged MBP was batch 
immobilized overnight at 4°C. The Ni-NTA resin was batch washed 3 times with 40 mL 
wash buffer (50 mM phosphate (pH 7.0) 300 mM NaCl, 10 mM imidazole). Resin was 
then transferred to a 5 mL disposable column and protein eluted with wash buffer 
containing 250 mM imidazole. Protein content of fractions collected from the Ni-NTA 
column was quickly assessed via 280 nm absorbance using a NanoDrop 1000 instrument 
(Thermo Fisher). Fractions containing protein were pooled and further resolved via FPLC 
using the NGC Medium Pressure Liquid Chromatography System and Enrich 70 
Superdex column (BioRad).  Fractions containing MBP were pooled, quantitated, then 






Gel electrophoresis (1% low melting temperature agarose (Sigma)) was 
performed on QDs assembled with native MBP to analyze the ratiometric assembly of 
MBP to the QD surface. QDs (7.5 pmol) were complexed with increasing ratios of MBP 
in DPBS at ratios ranging from 1:1 to 1:15 (QD:MBP) and allowed to incubate at room 
temperature for 30 minutes. QD-protein mixtures were subjected to electrophoresis for 15 
minutes and images were taken at 5 min intervals. 
 
Preparation of QD-MBP- βCD Conjugates 
Initial studies were performed to ensure that the MBP was fully loaded with the 
βCD conjugates before complexing them with the QD surface. First, aliquots of MBP in 
20% glycerol were washed to increase protein concentration and remove glycerol. To 
wash, 30 kDa Amicon® Ultra 0.5 mL filters (Millipore, MA) were loaded with 500 µL of 
MBP stock and spun for 10 minutes at 14K RPM. This procedure was repeated two 
subsequent times, all washes were performed in Hanks Buffered Salt Solution (no 
glucose) (HBSS). The concentrated MBP solution was spun off the filter at 1000 RPM 
for 2 minutes, achieving a 22X concentrated MBP stock. Using the concentrated MBP 
stock, an incubation solution containing 50 µM of MBP and 250 µM of either the βCD-
TF3 or βCD-DOX at a volume of 23 µL was incubated at 4oC overnight. For FRET 
analysis and cellular injections, the solution was diluted to 500 µL and spun using the 
Amicon filters to remove unincorporated βCD-conjugates; for analysis of maltose release 
the incubation solution was used with excess βCD. For cellular injections the loaded 




temperature (producing a 1:10 QD:MBP final ratio), or diluted and used for the FRET 
analysis described in the next section.    
 
Analysis of QD-MBP- βCD Conjugate Responsiveness 
 To determine the responsiveness of the QD-MBP-βCD-TF3/DOX constructs to 
varying concentrations of maltose, unfiltered βCD-loaded MBP was incubated at a ratio 
of 1:10 with 520 nm emitting QDs (7.5 pmol QD; ratio 1:10 (QD:MBP)) for 1 h at room 
temperature. Control solutions containing TF3 alone were included for all ratios to 
determine the contribution of direct TF3 excitation, this was not performed for the DOX 
constructs as DOX has negligible emission in the absence of DNA. The constructs were 
excited at 400 nm using a Tecan Infinite M1000 microplate reader and emission spectra 
was collected from 450-700 nm for the TF3 constructs and from 450-600 for the DOX 
constructs. After initial spectra were taken for each well to ensure uniformity, increasing 
concentrations of maltose were added to the wells at a 1:1 (v:v) ratio so the final 
concentration of maltose in each well equated to a range from 50 nM to 20 mM. The 
spectra were then measured for each maltose concentration. The FRET efficiency at each 
concentration was determined using the equation described in the Introduction: 




where FDA and FD are the fluorescence intensities of the QD donor in the presence and 
absence of the βCD -TF3/DOX acceptor, respectively. The emission profiles of the TF3 






To further analyze the FRET efficiency, increasing amounts of loaded MBP were 
complexed with 7.5 pmol of QD at ratios from 1:1 to 1:10 (QD:MBP). To ensure that the 
passivation of the QD surface by His6 binding was constant for each QD: MBP ratio, 
unloaded MBP was used to achieve a total ratio of 1:10 MBP (example; for a ratio of 1:3 
loaded MBP, a ratio of 1:7 unloaded MBP was added to the incubation solution). The 
spectra were measured to determine the FRET efficiency over increasing ratios of βCD-
TF3/DOX per QD.    
 The QD-TF3/DOX separation (r) distance for each ratio was determined 
according to the following equation: 











where R0 is the calculated Förster distance for the donor-acceptor pair. Data analysis was 
performed in Excel (ver. 14.0).  
 
Cellular Culture and Plating 
African Green Monkey kidney cells (COS-1) were cultured using T75 tissue 
culture flasks in complete growth medium (Dulbecco’s Modified Eagle’s Medium 
(DMEM; American Type Culture Collection ATCC)) supplemented with 10% (v/v) heat 
inactivated fetal bovine serum (ATCC) and 1% (v/v) antibiotic/antimycotic (Sigma). 
Flasks were incubated under a 5% CO2 humidified atmosphere at 37
oC and passaged at 
80% confluency. For microinjection, cells were seeded at a density of ~7 × 104 cells/mL 







Adherent COS-1 cells were injected using an Eppendorf FemtoJet® 4i 
microinjector controlled by an InjectMan® 4 micromanipulator in a manner similar to that 
described previously 109. Cells were prepared for injection by washing once with glucose-
free HBSS to remove excess media, then allowed to incubate for 5-10 minutes in fresh 
HBSS. The solution was then replaced with fresh HBSS prior to injection. The 
microinjection tip (Eppendorf Femtotips) was loaded with 5-10 μL of the 5 μM QD-
MBP-βCD-TF3/DOX constructs with excess βCD-TF3/DOX removed by filtration. 
Injection time (0.48 sec) and pressure (300 hPa) was maintained for uniformity of 
injection volume and to produce an even distribution of QDs throughout the cytosol. As 
an internal control for the QD-MBP-βCD-DOX injections, far red-emitting 655 nm QDs 
capped with CL4 at a concentration of 300 nM were added to the complexes prior to 
filtration and loading into the tip. 
 
Maltose Delivery 
After a minimum of 50 cells were microinjected with either the QD-MBP-βCD-
TF3 or QD-MBP-βCD-DOX constructs, dishes were transferred to a Nikon A1RSi 
confocal microscope and placed within a cellular incubator maintained at 37 °C. The area 
of microinjected cells was located with a 10x objective before moving to 60x oil 
immersion objective for imaging. For each time course, 5 locations were chosen per 
plate, 7 each 1.5 nm slices were taken per z-stack and 2x averaging was performed per 
512 x 512 pixel image. This timing allowed for an entire set of images to be captured in 1 




each maltose delivery. Maltose solutions in HBSS were added between the final image of 
time point one and the beginning of the second time point so that the final concentration 
of maltose in the plate ranged from 1.25 mM to 30 mM.  
 
Image Acquisition and Analysis 
Images were captured using the spectral imaging modality on the Nikon A1RSi 
confocal imaging system. Briefly, a 32 PMT array captured the intensity for a range of 
wavelengths as designated by the experimental setup. Three wavelength 'bin' sizes were 
available for use: 2.5, 6, and 10 which facilitate capture of a max wavelength range of 80, 
192 and 320 nm, respectively, where the PMT spectral range extends from 400 nm to 750 
nm. For our experimental setup, ranges were chosen to include the QD peak and the TF3 
(470 nm - 660 nm) or the QD and the far red QD control (480 nm - 740 nm), and given 
the scale of these ranges the largest bin size (10 nm) was chosen. The images produced 
by this setup were compilations of the intensities for each of the PMTs false colored for 
their delineated wavelength range. To include as much cellular cytosol as possible and 
because of the inherent dimness of a spectral image acquisition, the pinhole was set to 
maximum during image acquisition. As each PMT recorded a maximum intensity 
associated with its designated wavelength range, a spectral intensity profile was produced 
for each pixel within the image. To analyze this data, specific regions of interest (ROIs) 
were chosen to focus on the cytosolic environment and the spectral profiles for the 
brightest three slices (of the 7 originally captured) were exported into Microsoft Excel. 
These were then summed together to give the overall intensity for that ROI at that time 




samples) or for the normalized donor PL increase of the QD peak (DOX samples) was 
calculated for each ROI and averaged over all the individual ROIs taken at each 
concentration. Donor PL increase was calculated using Eq. 3, and the 520 nm QD peak 
intensity was normalized to the 655 nm QD peak intensity, which should not be affected 
by maltose delivery and remain somewhat constant throughout experimental acquisition. 
Analysis was performed in Excel and graphs were plotted using GraphPad Prism (V7).  
 
Fluorescence Lifetime Imaging Measurement (FLIM) 
Injected cells were also imaged using a ISS LSM upgrade system for the Nikon 
A1SRi on trial from the company. The system was set up with a 405 nm laser launch. 
The laser was either modulated by the data acquisition card (FastFLIM) or self-
modulated. FastFLIM (proprietary technology) was used as it is frequency based am dos 
faster and more sensitive than TCSPC (time domain) mode. The modulation frequency 
was set to 20MHz. To be delivered to the Nikon confocal head, the excitation laser beam 
was coupled to a single mode fiber. The coupling efficiency of laser into the fiber optic 
were around 30% (140 µW out of 350 µW input power). Prior to experimental imaging, 
the system was calibrated with a Coumarin 6 solution (2.55 ns) and a fluorescein solution 
(4.00 ns - a fluorescence standard) was tested to verify the system functioned as expected. 
Samples injected with the QDs alone were images first to determine the 520nm QD’s 
lifetime within the cytosolic environment, and measurements were taken over 12 minutes 
to determine stability and decay. This was also compared to the 520 nm QD’s lifetime 
with 10 unloaded MBP attached per QD, this data showed no change in the lifetime (data 




were measured before and after addition of 30 mM maltose to the cell solutions to 
determine the lifetime change in response to maltose addition.    
 
Results and Discussion 
Design and Rationale of Theranostic NP Actuation 
Efficient theranostic nanostructures depend on the specific and controlled release 
of cargo from the NP structure, and such a process requires careful design of the 
nanoparticle complex. To be effective, the NP complex must not only be easily traceable/ 
visualized, but the release of the NP-appended drug cargo must be induced with fine 
control. Importantly, both of these processes must be carried out with exquisite 
spatiotemporal resolution. With these goals in mind, we set out to produce a 
multifunctional nanoparticle composite that would remain unresponsive until the addition 
of an inert secondary triggering molecule. Ideally, that process could be monitored 
optically in real-time using FRET. Here we have designed a NP drug delivery system that 
is activated in a novel way. Rather than using ‘hard-wired’ modalities such as light 57, 
magnetic field 54-55, or ultrasound 61, here we induce drug release by simple addition of an 
inert molecule to the extracellular medium.  The addition of the inert sugar maltose 
triggers the release of the analog βCD by competitively displacing it from the binding 
pocket, thereby delivering the cargo to the cells. Monitoring this release is slightly varied 
for each of the systems, as can be seen in Figure 10 A/B. TF3 will undergo ‘standard’ 
FRET with the QD donor, and so two peaks will visible when the MBP binding pocket is 




Figure 10. Design of QD-MBP-βCD-dye- and –drug conjugate systems. A) 
Schematic of the QD-MBP-βCD -TF3 actuation system. βCD-TF3 bound within the 
MBP binding pocket results in FRET-sensitized emission of the TF3 from the 
photoexcited QD donor. Addition of maltose displaces the βCD-TF3 resulting in re-
emission of QD PL. B) Schematic of the QD-MBP-βCD-DOX actuation system. βCD-
DOX in the MBP binding pocket results in quenched QD luminescence with minimal 
emission from DOX. Addition of maltose results in release of the βCD-DOX and re-
emission of the QD donor. C) Absorbance and emission spectra for the 520 nm QD 
donor and TF3/DOX acceptors. Both the QD:TF3 and QD:DOX donor- acceptor pairs 
show significant overlap between the QD donor’s emission and the acceptor 
absorption. D) 520 nm emitting QDs capped with CL4 ligands were assembled with 
increasing ratios of His6-tagged maltose binding protein (MBP) as indicated and 
submitted to gel electrophoresis. Addition of increasing MBP/QD results in slower 




the addition of maltose, there will be competitive displacement of the βCD-TF3 from 
the binding pocket, and so the TF3 peak will disappear and the QD peak will increase. 
Given that the doxorubicin will not produce a secondary peak, the visualization of release 
will be dependent on the change in QD peak alone. Once the maltose is added, the βCD-
DOX will no longer be close enough to the QD to quench its emission and so the QD PL 
intensity will increase in response. 
 Given the ideal FRET donor properties of QDs, we utilized these particles as the 
NP scaffold and appended histidine-tagged MBP to the surface of the QDs. Into the MBP 
binding pocket was added the maltose analog βCD that was conjugated to TF3 or DOX. 
Once assembled, these constructs engage in FRET between the QD and the dye or DOX 
conjugates given the excellent spectral overlap of their absorbance with 520 nm QD 
donor emission (Figure 10C). The QD absorbance profile allows for excitation far in the 
UV, producing little direct excitation of the acceptor TF3 and the FRET can be further 
optimized by the addition of multiple donors per QD. It should be noted that DOX does 
not have a large molar extinction coefficient and so it acts merely as a quencher of the 
QD fluorescence, with no discernable QD sensitized emission from FRET 122. To 
determine the efficiency of MBP assembly to the QD scaffold, gel electrophoresis was 
performed with increasing ratios of His6 tagged MBP. The His6 tag interacts with the 
Zn2+ present in the QD shell via metal affinity coordination, and assembly is rapid 
(complete within minutes) and has been shown to be stable for days in cellular 
environments 93. Figure 10D shows the decreased migration of QDs through the gel 
matrix as a function of increasing MBP:QD ratios. This analysis showed that maximal 




ratio of 10 MBP per QD, a “smearing” pattern was seen and is indicative of a varied 
population of QDs which occurs when the number of proteins per QD, or valence, is 
assorted. Previous observations have shown this to be consistent with a Poissonian 
distribution at lower QD: protein valencies 76. To produce the largest visualizable FRET 
signal and potential cargo loading, a ratio of 10 MBP per QD was chosen to use for all 




Characterization of FRET Efficiency of QD-MBP-βCD Conjugates  
To ascertain the utility of the QD-MBP-βCD conjugate system, we first 
confirmed and quantified the FRET efficiency of the fully assembled conjugates. Figure 
11 A shows the resulting spectral traces collected from the QD-MBP-βCD-TF3 conjugate 
system where it was apparent that an increase in the number of MBP-βCD-TF3 
assembled onto the QD surface resulted in a concomitant decrease in QD donor 
Figure 10: FRET analysis of the QD-TF3 and QD-DOX donor-acceptor pairs. 
Figure 11: FRET analysis of the QD-TF3 and QD-DOX donor-acceptor pairs. A) 
Emission spectra of the QD-MBP-βCD-TF3 bioconjugates loaded with increasing 
MBP-TF3. Each spectra corresponds to the number of MBP-TF3 (loaded MBP) per 
QD and the balance of the QD surface (up to a ratio of 10 MBP) was made up with 
unloaded MBP. Spectra show decreasing QD PL and increasing TF3 PL that correlates 
with increasing loaded MBP per QD. B) Plot of the QD-MBP-βCD-TF3 FRET 
efficiency versus the number of loaded MBP per QD. Line is a fit to Eq 2 in Methods. 
C) Emission spectra of the QD-MBP-βCD-DOX system with increasing ratios of 
loaded MBP to unloaded MBP per QD show increasing QD PL that correlates to 
increasing loaded MBP. B) Plot of the QD-MBP-βCD-DOX FRET efficiency as 
function of number of loaded MBP per QD. Line is fit to Eq. 4 by using the calculated 
rDA values for each ratio and back-calculating what the corresponding FRET 




luminescence coupled with an increase in the sensitized emission from the TF3 acceptor. 
Control experiments were performed to ensure that the passivation of the QD surface by 
His6 binding was constant for each QD: MBP ratio (see Methods). Using these spectral 
data, the emission maxima for the donor and acceptor were plotted using Eq. 3 to 
determine the initial FRET efficiency at each QD:TF3 ratio. The R0 (the QD-TF3 
separation distance at which the FRET efficiency is 50%) for the QD-TF3 donor-acceptor 
pair was calculated using Eq. 1 to be 4.7 nm. These data were then analyzed using Eq. 4, 
which relates the FRET efficiency to R0 to determine the calculated QD donor-TF3 
acceptor distance (rDA) for each ratio of QD:MBP-βCD-TF3. This equation takes into 
account the contribution of increasing numbers of acceptors, n, assembled onto the QD 
surface. As shown in Figure 11B, the FRET efficiency clearly tracked with the number of 
acceptor complexes arrayed around the central QD donor, with maximal FRET efficiency 
of ~33% obtained at a ratio of 10 MBP-βCD-TF3 per QD. Further, this analysis resulted 
in a calculated center-to-center QD to TF3 distance (βCD-TF3 within the MBP binding 
pocket) of ~7.8 nm.   
 Similar analysis was performed on the QD-MBP-βCD-DOX conjugate system. 
As evidenced by Figure 11C, the decrease in QD donor luminescence again tracked with 
increasing numbers of MBP-βCD-DOX acceptors arrayed around the QD. In contrast to 
the TF3 system, however, negligible photoluminescent reemission from the DOX 
acceptor was observed as a function of QD quenching. This is not surprising given the 
modest molar absorptivity of DOX and the dependence of DOX-histone interactions on 
DOX emission 123. Nevertheless, DOX clearly quenched the QD donor in a ratiometric, 




acceptors revealed a considerable difference in the calculated center-to-center distances 
for the QD-DOX system compared to the QD-TF3 donor-acceptor pair. The separation 
distance for the QD-DOX pair was ~4.3 nm, which is ~3.5 nm shorter than that 
determined for the QD-TF3 pair. In this instance, it is likely that flexible carbon spacer 
(linear length ~ 1.4 nm) could allow the DOX to extend back to the βCD. This fact, 
coupled with the amphiphilic nature of DOX 124 and the role of the βCD as an efficient 
host for amphiphilic cargos (including DOX) 125, presents the possibility that the DOX 
associates with the βCD in a guest-host configuration despite the physical link; which 
would bring the DOX closer to the QD surface, resulting in the shortened separation 
distance observed here.   
 
Determination of Actuation Efficiency of QD-MBP- βCD Conjugates by Plate-based 
Assay 
Having successfully demonstrated that the QD bioconjugates engage in efficient 
FRET, we next determined the temporal responsivity and sensitivity of the QD-MBP- 
βCD-conjugates to the addition of maltose. To do this, microplate-based assays were 
performed in which MBP was first loaded with the each respective βCD conjugate (at a 
ratio of 1:5 MBP:βCD conjugate) to ensure complete loading of the MBP protein. Then, 
the loaded MBP proteins were assembled with QDs (1:10 QD:MBP) to form the full 
ensemble conjugates wherein the photoexcited QD donor was engaged in FRET with 
either the TF3 or DOX acceptor. Replicate wells of the microplate were loaded with the 




spectra were collected (data not shown). This served as an internal reference control to 
ensure that all of the replicate wells yielded uniform peak intensities prior to maltose 
addition (“unactuated” state).  Maltose was then added to the wells such that the final 
maltose concentration ranged from 50 nM to 20 mM. Immediately after delivery the 
spectra were again collected over the same range. Figure 12 A shows the resulting spectra 
for the response of the βCD-TF3 system to the addition of increasing concentrations of 
Figure 11: Responsiveness of QD-MBP-βCD-TF3/DOX systems to the addition of maltose. 
Figure 12: Responsiveness of QD-MBP-βCD-TF3/DOX systems to the addition of 
maltose. A) Emission spectra of the QD-MBP-βCD-TF3 complexes after addition of 
increasing concentrations of maltose.  Displacement of the βCD-TF3 results in 
increasing QD PL and decreasing TF3 PL that tracks with increasing maltose 
concentration. B) Plot of the QD-MBP-βCD-TF3 FRET efficiency versus maltose fit 
to a sigmoidal binding isotherm. C) Emission spectra of the QD-MBP-βCD-DOX 
complexes after addition of increasing concentrations of show increasing QD PL that 
correlates to increasing maltose concentration. B) Plot of the QD-MBP-βCD-DOX 
FRET efficiency as a function of maltose concentration. Curve is fit to sigmoidal 




maltose. There was a clear increase in QD emission and decrease in TF3 luminescence 
that tracked with the increasing maltose concentration added to the well. This provided 
strong evidence of the competitive displacement of the βCD-TF3 conjugate from within 
the MBP binding pocket by the exogenous maltose. The calculated FRET efficiency, 
when plotted as a function of concentration (Figure 12 B) resulted in an apparent binding 
dissociation constant (Kd) of ~10 µM, consistent with values reported in the literature 
126-
128. Comparable results were obtained with the maltose concentration-dependent studies 
on the QD-MBP-βCD-DOX conjugate. Here, only increased QD emission was observed, 
but the fit of the data to the binding isotherm resulted in a similar Kd value for that 
determined for the TF3 system. Collectively, these data gave us great confidence that not 
only did both systems engage in efficient FRET, but that the release of the βCD-TF3 or -
DOX cargo could be efficiently achieved by the simple addition of maltose.  
 
Intracellular Actuation of the QD-MBP-βCD Conjugate System 
In this study, our working hypothesis was that the self-assembled, multi-
component QD-MBP-βCD conjugate system could be introduced into the cytosol of cells 
and that the release of the appended cargo could be discretely controlled by the simple 
addition of exogenous maltose to the extracellular media. In this configuration, native 
sugar transporters resident in the plasma membrane transport the extracellular maltose 
into the cytosol where it induces the release of the βCD-conjugate from the MBP binding 
pocket. Our initial characterization showed that the conjugate system engaged in efficient 
FRET and that βCD-conjugate release could be induced by maltose in a concentration-




conjugate system to be actuated by the addition of maltose. To do this, we first confirmed 
that the complexes engaged in stable FRET in the cellular cytosol upon microinjection 
(Appendix Figure A2). This was accomplished by performing photobleaching studies on 
the QD-MBP-βCD-TF3 conjugates after injection into the cytosol. Spectral imaging of 
the complexes prior to photobleaching showed significant sensitized emission from the 
TF3 acceptor coupled with QD donor quenching. After bleaching of the TF3 acceptor by 
direct excitation with 561 nm laser, however, significant increased emission of the QD 
donor was observed. These data clearly demonstrated that the bioconjugate system 
engaged in FRET in the cytosol. 
Next, we characterized the time-resolved responsiveness of the QD-MBP-βCD-
TF3 system to the addition of extracellular maltose.  COS-1 cells were microinjected with 
the assembled complexes and initial imaging was performed to collect the baseline 
spectra. As expected, upon injection the complex was initially engaged in FRET, as 
evidenced by the strong yellow emission in the spectral image which is indicative of QD-
sensitized emission from the TF3 acceptor (Figure 13A). Maltose (20 mM final 
concentration) was then added to the extracellular medium and spectral imaging was 
performed at two minute intervals over a 30-minute period. This maltose concentration 
was selected as membrane glucose transporters, the putative transporters for maltose, 
exhibit Kd for glucose of ~15-20 mM 
129-130. After the addition of maltose, spectral 
imaging was performed every two minutes over a 30-minute window to monitor the 
change in FRET of the complex as a function of time as maltose was internalized into the 




FRET as an ~35% increase in QD donor emission was observed concomitantly with an 
~15% decrease in sensitized emission from the TF3 acceptor (Figure 13B). Control 
experiments wherein the FRET efficiency of the injected complex was monitored over 
this same 30-minute window without the addition of maltose showed negligible change in 
the QD/TF3 channels, demonstrating both the stability and responsivity of the complex in 
Figure 12: Response of intracellular QD-MBP-βCD-TF3 to maltose addition. 
Figure 13: Response of intracellular QD-MBP-βCD-TF3 to maltose addition. A) 
COS-1 cells injected with QD-MBP-βCD-TF3 were imaged in spectral mode (10 nm 
bins from 480 nm to 650 nm) using confocal microscopy. After initial image collection 
at t=0, maltose was added to the cell media to a final concentration of 20 mM. Images 
were taken every two minutes for 30 minutes. Panel shows the gradual color change 
from yellow at t = 0 min to green at t = 30 min, indicating decreased sensitization of 
the TF3 acceptor after displacement by maltose. Scale bar is 20 µm.  B) Spectral data 




the cellular cytosol. These data confirmed the time-resolved responsiveness of the QD-
MBP-βCD-TF3 system to the addition of extracellular maltose. 
Having demonstrated the utility of the intracellularly introduced QD-MBP-βCD-
TF3 bioconjugate system to respond to extracellular maltose, we next sought to perform a 
more quantitative analysis of the responsivity of the bioconjugate assembly as a function 
of both maltose concentration and time. Spectral imaging was performed on COS-1 cells 
loaded with the conjugate system in the cytosol. The cells were incubated with discrete 
concentrations of extracellular maltose (over a concentration range spanning 1.25 mM to 
30 mM maltose) and spectral imaging was performed over a 30 minute operational 
window. The data are shown graphically in Figure 14A where the change in the QD 
Figure 13: Time-resolved response of intracellular QD-MBP-βCD-TF3 to addition of extracellular maltose. 
Figure 14: Time-resolved response of intracellular QD-MBP-βCD-TF3 to addition 
of extracellular maltose. A) Separate dishes of plated COS-1 cells were injected with 
QD-MBP-βCD-TF3 conjugates and then increasing concentrations of maltose were 
added. Spectral images were collected over 30 min.  Plotted are the ratio of QD 
donor/TF3 acceptor peak height as a function of time. Data show that the βCD-TF3 is 
released quickly from the MBP binding pocket and is complete within ~6 min across 
all maltose concentrations.  B) Plot of the calculated initial rate of response (t=0 to t=4 
min) vs maltose concentration. Data are fitted with one site binding model shown in 




donor/TF3 acceptor PL emission ratio in response to extracellular maltose are plotted as a 
function of time. For each increasing concentration of maltose, a clear dose-dependent 
increase in the QD donor/TF3 acceptor PL emission ratio was observed. Notably, the 
slope of the initial rates of change in QD/TF3 emission ratio tracked positively with 
increasing maltose concentration and, within each maltose concentration, maximal 
displacement of the βCD-TF3 ligand was achieved in ~6 min. It is also important to note 
the inherent stability of the assembled complex, for in the absence of added maltose, 
there was negligible change observed in the QD/TF3 emission ratio. When the initial 
rates were plotted versus maltose concentration and fit to a one-site binding model 
(Appendix Figure A3), a calculated Kd of ~6.5 mM for the internalization of maltose was 
determined (Figure 14B). This value agrees well with that reported in the literature for 
the intracellular transport of maltose 129-130. It is important to note that the Kd calculated 
for this system is an apparent Kd that includes both the rate of maltose internalization and 
the rate of release of the βCD-TF3 from the binding pocket of the MBP. The 
experimental setup does not allow for the contributions of each rate to be determined, but 
given how quickly each of the concentrations reaches their final values, it can be 
hypothesized that the limiting factor is the cells’ ability to internalize maltose. This 
makes sense as the cells want to maintain a certain osmolarity and the rapid 
internalization of maltose would eventually be slowed to ensure that the cells remain 
viable. Fluorescence lifetime imaging confirmed that the assembly was engaged in FRET 
as the QD donor exhibited a ~20 % decrease in fluorescence lifetime in the intact 
bioconjugate. However, upon addition of 30 mM maltose, and displacement of the βCD-




(Appendix Figure A4). Cumulatively, these data demonstrate the ability of the QD-MBP-
βCD-TF3 bioconjugate system to serve as a robust actively triggered actuation modality 
that responds to extracellular maltose in a manner that is consistent with the known 
affinity of membrane transporters for the sugar. 
Building on the demonstrated utility of the QD-MBP-βCD-TF3 system to be 
triggered by extracellular maltose, we next sought to use the conjugate system to deliver 
DOX, a potent chemotherapeutic whose delivery must be tightly controlled to avoid off-
target tissue toxicity. The QD-MBP-βCD-DOX system presents a few variations from the 
TF3 system such that the experimental approach had to be slightly modified. First, 
because the DOX acceptor is minimally emissive, spectral imaging allowed the 
monitoring of the DOX channel only. Second, because DOX-induced toxicity has been 
shown to result in changes in cell/nuclear size 40 that could potentially affect QD PL, red-
emitting (655 nm) QDs were co-injected into the cytosol along with the QD-MBP-βCD-
DOX complexes. In this way, the 655 nm QDs served as a cross-channel internal imaging 
control. 
In similar fashion to the βCD-TF3 system, the QD-MBP-βCD-DOX system also 
showed a similar time-dependent re-emission of the QD donor when 20 mM maltose was 
added to the media (Figure 15A). Importantly, the 655 QD imaging control showed no 
change in its luminescence, confirming that the observed increases in QD PL were due to 




A time-resolved plot of the rate of donor QD PL recovery showed the displacement of the 
βCD-DOX from the MBP is rapid, occurring within 10 minutes with a calculated Kd for 
the intracellular transport of maltose of ~1.1 mM which agrees well with that determined 
for the βCD-TF3 system, but is also an apparent Kd for the system, and could vary 
Figure 14: Response of intracellular QD-MBP-βCD-DOX to maltose addition. 
Figure 15: Response of intracellular QD-MBP-βCD-DOX to maltose addition. 
A) COS-1 cells injected with QD-MBP-βCD-DOX conjugates were imaged in 
spectral mode using confocal microscopy. After initial image collection at t=0, 
maltose was added to the media (final concentration 20 mM). Images were taken 
every two minutes for 30 minutes. Panels show the progressive increase in QD PL 
over the 30 min window, indicating the maltose-induced release of the βCD-DOX 
from the MBP binding pocket. Inset in each panel shows the emission intensity for 
the 655 nm QD imaging control for a cell outside the current view. Scale bar is 20 
µm.  B) Spectral data corresponding to the cells in (A). A time dependent increase 




slightly due to the βCD-DOX binding to the MBP in a less-efficient manner than the 
βCD-TF3 (Figure 16B). This was also confirmed by FLIM imaging where the quenched 
lifetime of the QD donor in the intracellular QD-MBP-βCD-DOX complex (~15%) was 
recovered after the addition extracellular maltose (Appendix Figure A4). Interestingly, 
there was a modest degree of release of the βCD-DOX moiety in the absence of added 
maltose, suggesting subtle differences in the way the βCD-DOX interacts with MBP 
binding pocket compared to the βCD-TF3 conjugate. It is likely that the amphiphilic 
nature of DOX, coupled with the flexible linker bridging the βCD and DOX, promotes 
guest-host interactions between the βCD and DOX that result in a lower-affinity 
interaction of βCD-DOX with MBP. Further supporting evidence for the altered activity 
of DOX in the βCD-DOX conjugate come from control studies of its nuclear uptake 
Figure 15: Time-resolved response of intracellular QD-MBP-βCD-DOX to addition of extracellular maltose. 
Figure 16: Time-resolved response of intracellular QD-MBP-βCD-DOX to 
addition of extracellular maltose. A) Increasing concentrations of maltose were added 
to replicate seeded plate of COS-1 cells that were injected with QD-MBP-βCD-DOX 
conjugates and then increasing concentrations of maltose were added and spectral 
imaging was subsequently performed at 2 min intervals over a 30 min period. Plotted 
are the calculated FRET E using Eq. 3 normalized to the initial timepoint. (I/ Io) B) Plot 
of the calculated initial rate of response (t=0 to t=4 min) vs maltose concentration. Data 




compared to free DOX (Appendix Figure A5). While free DOX localized efficiently 
within the nucleus, βCD-DOX accumulated at the nuclear membrane, providing evidence 
that conjugation to βCD altered its innate nuclear uptake and DNA-binding properties.  
 
Conclusions 
The data presented here provide strong evidence of the utility of the novel 
actively-triggered self-assembled QD-based drug delivery system. The actuation 
modality is driven by the simple addition of an inert triggering molecule, maltose, to the 
extracellular environment. The multiple parts of the NP-bioconjugate system are easily 
assembled and the ensemble conjugate is directly introduced to the cytosol by 
microinjection, which bypasses the endolysosomal system, and allows for direct 
assessment of the system’s responsiveness to the addition of the maltose to the 
extracellular media. The system responds in a dose- and time-dependent manner to affect 
the release of both dye- and drug-conjugates of βCD with similar release profiles 
observed for both ligand systems. FRET-based imaging allows for the real-time tracking 
and characterization of maltose-induced ligand release. This novel actuation modality has 
the benefit of not being dependent on light-mediated stimulation (which has limited tissue 
penetration) or the use of bulky, dedicated equipment (e.g., magnetic field, 
radiofrequency) in a centralized facility.  Future work could explore the potential range of 
sizes that the system could transport and also modify the binding efficiency of the 
bridging protein- potentially producing a variety of release rates specific to the desired 




Chapter 4: Design and Implementation of an Extracellular pH Sensor 
 
Introduction 
Cancer accounted for over half a million deaths in the United States of America in 
2014, making it the second leading cause of death in the country 131. As cancer is defined 
as the uncontrolled growth of abnormal cells in a part of the body, any cell type can 
become cancerous - making a singular ‘cure for cancer’ a near impossibility. Initiation of 
abnormal cell growth is caused by the mutation of DNA in two types of specific genes, 
tumor suppressor genes (genes whose loss ‘turns on’ cancerous growth through inhibition 
loss) and oncogenes (genes that, once mutated, cause cancer) 132. As there are numerous 
possibilities for these types of mutations, the cancer present in one individual can be 
almost unique when compared to another’s cancerous cells. However, there are some 
commonalities between almost all cancer types, the most well-known of which being 
tumor formation - where a large centralized conglomeration of abnormal cells grows in 
an uncontrolled manner 133. These tumors can be benign, where they do not release cells 
into the bloodstream to form secondary tumors, or malignant, where cells traverse the 
body and form many secondary smaller tumors. Tumors commonly modify their 
extracellular environment to better suit their prolific growth. First, tumors excrete 
vascular endothelial growth factor (VEGF) that stimulates the formation of new 
vasculature to the tumor site therefore increasing the blood supply to the tumor site 134. 
The vasculature in the tumor environment also displays what is called the EPR effect, 
where there is an enhanced perfusion and retention within the tumor locale 135. Many 
drug delivery mechanisms attempt to take advantage of this leaky vasculature, where they 




in the tumor location and can more easily extravasate across the epithelium 136. One other 
prominent feature of the tumor microenvironment is their lower pH compared to normal 
physiological conditions. Tumors can have pH microenvironments as low as pH 5, which 
is significantly lower than the 7-7.4 pH seen in healthy tissue 95. Measurement of the pH 
in the extracellular tumor environment could assist in the design, implementation and 
monitoring of more targeted release agents. However, this is not something easily 
achieved with currently available techniques as described in the following section. 
 
Current pH Sensors 
Many common pH sensors that are used in cellular applications focus on the 
change that occurs within the endolysosomal internalization process. As vesicles are 
shuttled from the cell surface, the pH within those vesicles gradually lowers to reach a 
final pH of 5 within the lysosomes. Commercially available sensors like pHrodoTM 
proprietary dyes, available from ThermoFisher, are designed to be internalized and 
increase in intensity as the pH of their environment decreases. This is a ‘turn on’ type of 
measurement that makes it difficult to quantifiably measure the actual pH of the 
environment. The sensor 2',7'-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein 
(BCECF, ThermoFisher) can give a more precise pH measurement but requires the 
sample to be excited at both 440 nm and 490 nm wavelengths, which is difficult on most 
microscopes. As mentioned in the Introduction, many labs use the pH-responsive 
properties of FITC in the design of pH sensors. Fluorescein exhibits pronounced pH 
dependent absorption and fluorescence features due to its intrinsic multistage 




hypochromic shift while the fluorescence intensity concurrently decreases as well 137-138. 
Xu et al. used FITC and the pH-unresponsive dye Ru(phen)3
2+ as a ratiometric pH 
indicator by encapsulating the Ru(phen)3
2+ within silica particles decorated with 
covalently-bound FITC. This complex produced a single-excitation (450 nm) 
measurement system that displays a change from green to red during internalization in 
SMMC-7721 hepatoma cells 139. Other pH-responsive systems have been designed using 
alternative fluorescent molecules as the monitoring component for intracellular pH 
sensing systems. The Parak Lab produced polyelectrolyte microcapsules loaded with pH-
responsive SNARF-1-dextran that could be internalized and showed a change from red 
fluorescence in alkaline cell media to a green fluorescence in the acidic endosomal 
environment of MDA-MB435S breast cancer cells 140. Dennis et al. used a GFP analog 
called mOrange that was appended onto a 525-nm emitting QD for a FRET-based 
intracellular pH sensor, and after internalization in HeLa cells the intensity of the 
mOrange decreased in response to the lowering of pH. This system produced PL changes 
across a dynamic range between pH 6 and 8, and was designed to overcome some of the 
limitations in imaging fluorescent probes over long periods of time (i.e. 
photobleaching)87.  
While there are a wide variety of intracellular pH sensors, there are very few 
sensors that are specifically designed for extracellular pH sensing. One method utilizes 
amphiphilic lipid-DNA molecules labeled with one of two fluorescent molecules, a green 
pH sensitive dye fluorescein (FAM) and an orange pH insensitive dye 
carboxytetramethylrhodamine (TAMRA) which can be co-localized with the extracellular 




however, is limited by the FAM’s responsive range, which is very close to that of FITC 
given their structural similarities, and so the dynamic range that can be measured is only 
from pH 6-8. This system uses direct excitation of the FAM and so is very susceptible to 
photobleaching which is problematic for long-term tumor microenvironment studies 141. 
Another extracellular pH sensing approach does not focus on labeling the cellular 
membrane, per se, but rather on developing a blood-stream circulating sensor that uses 
red blood cell ghosts loaded with the FITC. The ghosts equilibrate quickly to the 
extracellular blood pH using the chloride-bicarbonate exchanger inherent in their cell 
membranes. This produces a sensitive system that has potential to act as a long-term 
blood sensor 142. This system travels rapidly throughout the body with blood flow, 
however, and so would give an overall measurement of the pH and will not be able to 
specifically measure a singular location with high precision. Our study attempts to 
overcome some of these limitations by using a new FRET-based sensor design combining 
a QD donor, a pH-responsive dye, and a unique peptide that labels the cellular membrane 
with a high degree of accuracy.       
       
JB858: A Unique Membrane-Labelling Peptide 
We have previously published work using short peptide sequences and their effect 
on the localization of QDs after delivery. The original peptide in those studies was shown 
to have promising results in delivering palmitoyl-protein thioesterase 1 (PPT1) inhibitors 
to neurons 143-144. These inhibitors are particularly of interest as they are chaperones in 
infantile Batten disease. This peptide, called JB577, has the following sequence:  




diaminopropionic acid (Dap) to a diaminobutyric acid (Dab), which amounts to the 
addition of one methyl group between the peptide backbone and the palmitoyl, yielded a 
very different functionality for the peptide. The sequence of the new delivery peptide, 
dubbed JB858, is WG(DabPal)VKIKK(P9)GG(H6), where the palmitoyl group is anchored 
to a Dab residue by a nonhydrolyzable amide linkage.  The His6 QD-coordination 
sequence is followed by the Gly2 flexible linker and the Pro9 motif.  The Pro9 is expected 
to form a rigid type II helix to help the (DabPal)VKIKK segment extend out beyond the 
surrounding PEG layers on the QD surface.  The positively-charged VKIKK motif is 
supposed to mediate electrostatic interactions with cellular membranes while the 
palmitoyl group is thought to insert into the membrane allowing the QD to remain 
membrane-bound. Cells labeled with QDs conjugated with JB858 preferentially localized 
to the cellular membrane over the studied time periods (up to 48 hours). This prolonged 
labeling is ideal for live-cell monitoring of the extracellular pH. 
In this study, we utilize one of the least developed areas of the visible 
fluorescence range (below 500 nm) for QD materials and tap into their potential for 
FRET-based pH sensing. The hydrophobic 464 nm emitting QDs synthesized for this 
purpose were modified by ligand exchange with compact hydrophilic ligands to evaluate 
the biocompatibility of the QDs for biological sensing and imaging studies.  These water-
soluble blue-emitting QDs exhibited reasonably high QYs (20-30%), narrow 
photoluminescence bands, and excellent pH and salt stability 145. Conjugating these 
nanocrystals with the pH-responsive FITC produces a FRET-based nanoscale pH sensor, 
as the QD emission profile overlaps the FTIC’s absorption profile. Fluorescein itself is 




a robust sensing system, but using the aforementioned blue QDs as a FRET donor will 
offer some protection to FITC molecules attached to the QDs as they can be sensitized 
during signal transduction and not directly excited. This QD-FITC sensing system can 
label cells using the JB858 peptide, producing an extracellularly localized pH sensor that 
has a dynamic range specific to that commonly seen in tumor microenvironments. 
Additionally, this system is reproducible and comparison to a standard titration curve can 
correctly identify the pH of an unknown buffer within 3% of the measured pH.    
   
Experimental 
QD-FITC Coupling and pH Sensing Assay 
Typical reaction conditions used were as follows:  464 nm emitting QD coated 
with DHLA-PEG750-OMe:DHLA-PEG600-NH2 (4:1) (12.0 µM, 250 µl, 3.0 × 10
-9 mol) 
was mixed in 500 µl of 0.1 M NaHCO3/Na2CO3 buffer (pH 9). The DHLA-PEG600-NH2 
was used to conjugated the FITC to the QD surface. The specific synthesis of these QDs 
is described in 145 and to conjugate FITC to the 464 nm QDs, a FITC solution (3.41 mM 
in DMSO, 18 µl, 6.1 × 10-8 mol) was added to the QD solution to initiate the reaction.  
After gentle stirring for 7 h in the dark at room temperature, the mixture was directly 
loaded onto a PD-10 desalting column (GE Healthcare Life Sciences) and eluted with 
0.1× PBS 146. Elution of the QD product (band) was traced by hand-held UV lamp. The 
first emitting single band was collected and transferred to a centrifugal purification unit 
(Amicon Ultra 30K, Millipore). The product solution was diluted with DI water and 




QD solution was used for subsequent pH sensing experiments.  Buffer solutions used are 
as follows: 0.1 M AcOH + 0.1 M NaOAc for pH 3-6; 50 mM Tris + HCl for pH 6.5-9. 
 
Cell Culture and Cytotoxicity Test 
African-green monkey kidney cells (COS-1) were maintained in complete growth 
medium (Dulbecco’s Modified Eagle’s Medium (DMEM; American Type Culture 
Collection (ATCC)) supplemented with 10% (v/v) heat inactivated Fetal Bovine Serum 
(FBS; ATCC) and 1% (v/v) antibiotic/antimycotic solution (Sigma-Aldrich) at 37 °C and 
5% CO2.  The cells were cultured in T75 flasks under a humidified atmosphere and 
passaged at 80% confluency. 
The water-soluble QDs were conjugated to the membrane localization peptide 
JB858147 by incubating the assemblies at a QD:peptide ratio of 1:30 in DMEM 
supplemented with 25 mM HEPES (DMEM/HEPES, pH 7.4; Life Technologies, 
Carlsbad, CA). To ensure that no aggregation occurred in response to the incubation, 
each component was mixed following a specific protocol.  First, the peptides were 
suspended in DMSO, and the DMSO solution was further mixed with DMEM/HEPES 
buffer so that the final DMSO concentration was 5 % (v/v). Second, the QDs were added 
to the peptide solution, vortexed, and allowed to incubate for 30 minutes; after which the 
solution was spun briefly to ensure that no aggregation had occurred.  The final 
concentration of the QDs were 500 nM. For cytotoxicity analysis, cellular proliferation 
was analyzed using the CellTiter 96® AQueous One Solution Cell Proliferation Assay 
(Promega, Madison, WI) by following the manufacturer’s prescribed instructions.  The 




viable cells at the assay end point.  Briefly, 96-well plates were seeded with ~2 × 103 
cells/well and allowed to incubate overnight. The cells were then exposed to increasing 
concentrations of the QDs for 30 min in DMEM/HEPES.  The solutions were removed, 
the cells were washed with DMEM/HEPES, and replaced with complete media.  The 
cells were cultured for further 48 hours before performing the assay.  A control of 
DMEM delivery was performed to standardize the results, and media alone was used as a 
blank control. 
 
QD-FITC Delivery to Cellular Membranes Using Peptide JB858 
For QD-FITC delivery and attachment to cellular membranes, 14 mm dishes 
(MatTek Corporation; Ashland, MA) were seeded with ~2 × 105 cells per dish and 
allowed to incubate overnight. The QD-FITC conjugates were assembled with the 
membrane targeting peptide JB858 by incubating the conjugates at a QD:peptide ratio of 
1:40 in DMEM/HEPES.  The final concentration of the QDs and JB858 were 200 nM and 
8 μM, respectively. The QD-FITC-JB858 assemblies were incubated on pre-washed cells 
for 30 minutes, washed, and the media was changed to Dulbecco's phosphate-buffered 
saline (DPBS) 147. 
 
Acquisition and Image Analysis of Extracellular pH Sensing 
The cells were subsequently imaged on a Nikon A1RSi confocal microscope 
using spectral acquisition from 440 to 625 nm binned over 5 nm.  A 405 nm laser was 
used to excite the sample in the same manner as normal confocal microscopy, and the 




cassette which was set at 5 nm resolution. The output was then focused onto a 32 photo-
multiplier tube (PMT) array which acquires the output from each of the 5 nm bins and 
produces images and intensity data.  The resulting image is a compilation of each of the 
wavelengths and provides intensity data for each specific wavelength bin.  To explore pH 
effects on the fluorescent profiles of the QD-FITC conjugates attached to the cell 
membranes, the cells were iteratively incubated in buffers of decreasing pH values.  In 
between each media exchange the cell monolayers were washed twice.  After each image 
was taken, multiple regions of interest (ROI’s) were chosen at centers on the membrane 
and the spectral intensity data were exported into Excel for analysis.  Images were 
processed using Nikon Elements 4.50.00.  As a control, the same QD-FITC conjugates 
were assembled with JB858 at a QD:peptide ratio of 1:15 in DPBS with each desired pH, 
and the fluorescence spectra of each sample were measured using the Tecan microtiter 
plate reader. 
 
Results and Discussions 
Ligand Exchange to Produce Biocompatible Blue-Emitting QDs  
Directly following synthesis, the ZnSe/CdxZnx-1/ZnS multishell QDs, where the 
Cd is ratiometrically exchanged with Zn ions (to produce x amount of Cd and x-1 of Zn), 
are coated with their native hydrophobic surface ligands 145.  For use in biological 
applications, they must be made colloidally stable for use in aqueous environments.  The 
as-prepared QDs were further modified via ligand exchange with hydrophilic ligands to 
demonstrate that they are both compatible with common surface modification techniques 




photophysical properties. The surface ligand used for this study is a poly(ethylene glycol) 
(PEG) appended thiolated ligand DHLA-PEG750-OMe 
69, and a pre-metallation method 
was adopted for ligand exchange 148. We, along with many other groups, have previously 
demonstrated that DHLA-based thiol ligands and their derivatives provide QDs with 
enhanced colloidal stability over a wide range of buffer conditions due to their 
multidentate structures 75, 149-153. To further facilitate ligand exchange in a gentle manner, 
a two-step ligand exchange method was also incorporated as described 154. 
We compared the absorption and fluorescence spectra of the blue-emitting QDs 
before and after ligand exchange 145.  The spectral shape and position of the lowest 
absorption band after ligand exchange were essentially the same as those of the newly 
synthesized QDs, and the same trend was observed for the fluorescence spectra as well. 
This indicates that the intrinsic photophysical properties of the QDs were preserved 
during the ligand exchange. QYs of the blue-emitting QDs before and after ligand 
exchange were also measured.  For ligand exchange of conventional CdSe/ZnS QDs, a 
~50% or more decrease in QY after ligand exchange compared to the parent QD 
materials has been commonly reported 112, 149, 155. While the current blue-emitting 
multishell QDs prepared in this study still showed a ~20-45 % decrease in QY after 
ligand exchange, the values in water were still relatively high (QY ~0.2-0.3) compared 
with the original values measured for the as-prepared ZnSe/CdxZnx-1/ZnS QDs.  We 
surmise that the multishell formation helped to protect the ZnSe core, and the CdxZn1-xS 
layers in between the ZnSe core and ZnS outer layers alleviated the lattice mismatch 




minimum surface strain, the QD fluorescence is expected to be less sensitive to surface 
modifications and reduction of the QY following ligand exchange can be minimized.   
To assess the long-term colloidal stability of the blue-emitting QDs coated with 
our hydrophilic ligands, 0.5 µM blue-emitting QDs coated with DHLA-PEG750-OMe 
were dispersed in a wide range of pH buffers from pH 2 to 13 (Figure S9 in 145).  QD 
solutions showed good colloidal stability from weakly acidic (pH ≥ 3~4) to basic pHs.  At 
lower pHs (pH ≤ 3~4), a partial or complete fluorescence quenching and sedimentation 
were observed similar to the results seen with CdSe/ZnS QDs coated with multidentate 
thiol ligands 75, 149.  The strongly acidic buffer results in “acidic” etching of the QD 
surface as well as destabilizing the ligand-to-QD coordination due to protonation of the 
thiol anchoring groups. The remaining QD dispersions were colloidally stable in weakly 
acidic to strongly basic pH conditions (pH 5~12) without apparent fluorescence 
quenching for at least one year.  In a similar manner, the colloidal stability of QDs coated 
with DHLA-PEG750-OMe were examined under high salt concentration as well (data not 
shown).  QDs were dispersed in 3M NaCl aqueous solution and the fluorescence of the 
colloidal solution was monitored over time. The QDs remained stable for over a year 
without any visible sign of aggregation or quenching.   
Not only is long-term QD stability fundamental for biological applications but the 
issue of toxicity can also be exceedingly important when working with cells and tissues 
83, 156.  We thus examined the cytotoxicity potential of blue-emitting QDs coated with 
DHLA-PEG750-OMe on COS-1 cells using a standard colorimetric tetrazolium-based 
cell proliferation assay.  This assay is commonly used to monitor inhibition of cellular 




concentration ranges of unconjugated QDs and QDs conjugated to JB858 were exposed 
to COS-1 cells.  Following washing, and a subsequent 48 h culture, we found no 
detrimental changes in proliferation for either unconjugated QDs (tested up to 200 nM) or 
QD-peptide assemblies (QD:peptide ratio of 1:30) relative to the untreated control 
(Figure 17E). We should note that no apparent toxicity has been observed for the same 
peptide when directly exposed to the cells alone as controls 147. Delivery of CdSe/ZnS 
QDs coated with the same ligands has also been demonstrated not to impair viability and 
proliferation in various cell lines and developing tissues147, 156, 158. 
 
Ratiometric pH Sensing Assay  
We then coupled the QDs to fluorescein to construct a QD FRET-based 
ratiometric pH sensing system 87, 159. When used as FRET donors the fluorescence of the 
blue-emitting QDs can provide significant spectral overlap with the fluorescein acceptor 
absorption (450 to 500 nm). The 464 nm emitting QDs applied here have a reasonably 
high spectral overlap with fluorescein (Förster distance R0 of 4.1 nm at pH 9) while its 
narrow fluorescence band is still well separated from the fluorescein emission allowing 
for a simple direct analysis without requiring spectral deconvolution.  The conjugation 
chemistry using the current surface ligands is expected to keep the QD and fluorescein 
close enough for efficient energy transfer. Moreover, the ability to decorate the QD donor 
with multiple fluorescein acceptors will also increase the FRET efficiency since it 
proportionally increases the acceptor cross section and manifests practically as a larger R0 




In order to make the QD amenable for surface conjugation, the 464 nm emitting 
QDs were prepared using a 4:1 mixture of DHLA-PEG750-OMe/DHLA-PEG600-NH2.  
The terminal amine groups on the QD surface provide a chemical handle for coupling to 
fluorescein isothiocyanate (FITC) which forms a stable thiourea bond with it (Figure 
17A).  In the labeling reaction, the amine-terminated QDs were mixed with a ~20-fold 
excess FITC in pH 9 buffer, the reaction mixture was stirred at room temperature in the 
dark for several hours and directly passed through a gel filtration column to remove the 
unbound dyes.  During the conjugation reaction and subsequent purification, the QD 
solution showed no apparent sign of aggregation or precipitation.  FITC conjugation on 
the QD surface was confirmed by agarose gel electrophoresis (Figure 17B).  The pKa of 
the amine group is ~9, and therefore the QD surface is expected to be positively charged 
to some degree in 1× TBE buffer (pH ~8.3).  Corresponding to this, the 464 nm emitting 
QDs capped with 20% DHLA-PEG600-NH2 move towards the cathode under the applied 
electric field.  The low QD mobility is presumably due to low surface coverage (20%) of 
the amine functional groups and the presence of the neutral methoxy groups in 
conjunction with the cumulative contributions from all the neutral PEG groups.  On the 
other hand, free FITC moved toward the anode with high mobility due to its small size 
and negatively charged carboxyl groups.  QD-FITC conjugates showed low mobility 
toward the anodic electrode since the positive charges of the amine terminal groups on 
the QDs were now masked by thiourea bonds and the negative charges of FITCs bound 
on the QDs counter the influence of any remaining unbound amines. FITC conjugation 
on the QD surface was also assessed using dynamic light scattering (DLS) measurements 




PEG750-OMe/DHLA-PEG600-NH2 (4:1) was estimated to be 13.0 ± 0.5 nm.  The hard 
diameter of the 464 nm emitting QD sample measured by TEM was 7.1 ± 0.52 nm. These 
measurement values are an average of at least 100 QDs for each sample.  The difference 
between hydrodynamic size and the hard core/shell size arises from the hydrodynamic 
interactions of the ligand layer with the surrounding buffer 76. The contribution of the 
surface ligands to the hydrodynamic radius is ~3 nm, which falls within the range 
previously measured for different sized DHLA-PEG750-OMe-coated QDs 
75, 154.  The 
conjugation of multiple FITC dyes at the terminal amine groups of the PEG ligands led to 
only slight increase of the hydrodynamic size (13.9 nm ± 0.2 nm).  DHLA-PEG600-NH2 is 
shorter than DHLA-PEG750-OMe and serves to minimize any increase in the 
hydrodynamic size after FITC conjugation.  Compact hydrodynamic size after FITC 
conjugation is also crucial to ensure efficient FRET between the QD and FITC and 
further reflects the excellent colloidal stability of the QD-FITC conjugates following 
chemical modification and purification steps. The absorption spectrum of the QD-FITC 
conjugates was easily deconvoluted into a simple sum of the individual spectra of QD 
and fluorescein dye, and the average number of conjugated FITC dyes per QD was 
estimated to be ~13.9 145.  The QD-FITC conjugate fluorescence spectrum also showed 
two major peaks at 464 and 523 nm corresponding to the QD and FITC, respectively 




For the ratiometric pH sensing assay, the conjugates were excited at 400 nm, 
where the absorption of FITC is lowest to minimize its direct excitation.  The assay was 
carried out by monitoring the FRET acceptor intensity/donor intensity ratio, where the 
acceptor intensity corresponds to the FITC peak emission at 523 nm and the donor 
intensity corresponds to the QDs emission at 464 nm. Fluorescence peak intensities were 
monitored directly without correction since there was almost no spectral leakage at each 
fluorescence peak position from its counterpart.  The intense FITC fluorescence signal at 
Figure 16: 462 nm QD- FITC FRET construct analysis. 
Figure 17. 464 nm QD- FITC FRET construct analysis. (A) Schematic 
representation of aqueous conjugation chemistry between the 464 nm emitting QDs 
coated with DHLA-PEG750-OMe:DHLA-PEG600-NH2 (4:1) and FITC. (B) Gel 
electrophoretic separation of (i) the blue-emitting QDs coated with DHLA-PEG750-
OMe:DHLA-PEG600-NH2 (4:1), (ii) the QD-FITC conjugates, and (iii) FITC. Gels were 
run on 0.8% agarose gel in 1×TBE buffer (pH 8.3) at ∼12 V/cm for ∼30 min. The 
yellow dotted line indicates the position of wells. (C) Photoluminescent changes of the 
QD-FITC conjugates in different pH buffers.  The sample was excited at 400 nm. (D) 
Plot of the FRET ratio (A(523 nm)/D(464 nm)) of the QD-FITC conjugates as a function 
of pH. (E) Cytotoxicity assay results demonstrating the effects of 483 nm emitting 
CdZnSe/Cd0.1Zn0.9S/ZnS core/shell QDs coated with DHLA-PEG750-OMe (blue line) 




523 nm at higher pH reflects FRET from the QD to the FITC bound to the PEG terminal.  
Excitation of the same concentration of FITC solution at 400 nm showed only ~6% of the 
fluorescence intensity of the QD-FITC conjugates, confirming significant sensitization of 
the FITC (data not shown). Analysis of the spectral data showed the FRET efficiency at 
pH 9 was 96.5%.  As the pH was lowered, FITC fluorescence intensity decreased 
concomitant with a gradual recovery of the QD fluorescence (Figure 17C).  Clearly, the 
changes to the pH-dependent spectral overlap between the QD and FITC drives the pH 
dependent spectral behavior of the QD-FITC conjugates.  The FRET ratio increased with 
pH manifesting a generally sigmoidal function from pH 3 to ~7.5 (Figure 17D).  Beyond 
pH 8, the FRET ratio was saturated and decreased slightly.  In particular, the FRET ratio 
showed the most dynamic changes between pH 5 and 7, an ideal range for tumor 
microenvironment measurement.   
Since ratiometric pH sensing in acidic buffers was successfully demonstrated, we 
next explored the conjugates pH sensing capability in extracellular environment. As 
nanoscale materials that are exposed to cells typically undergo endocytosis and 
subsequent cellular internalization, development of a technology to image acidic cellular 
microenvironments without the sensor itself being subjected to endocytosis is 
fundamental to detecting tumors and characterizing the relevant extracellular 
microenvironments. To accomplish this, we complexed the QD-FITC conjugates to the 
previously described JB858 peptide which localizes QDs to the plasma membrane stably 
for up to 48 hours following cellular exposure 147. JB858 was self-assembled on the QD-
FITC conjugates at 1:40 QD:peptide molar ratio in DMEM/HEPES buffer just by simple 




labeling and the fluorescence signal was monitored at different extracellular pHs using 
DPBS as the extracellular media.: 464 nm QD-FITC Sensor Efficacy. 
            As can be seen in Figure 18A, the majority of QD-FITC conjugates effectively 
labeled the plasma membranes.  The green emission at pH 7 and 8 reflects that the 
fluorescence signal was dominated by FITC as expected from the pH sensing 
experiments described above.  With stepwise decreases in pH down to 3 using buffer 
exchange, the emission color of the QD-FITC conjugates bound on the membranes 
progressively changed from green toward blue.  The fluorescence spectra from 440 nm to 
625 nm measured in 5 nm binned wavelengths were compiled for each of the pH levels   
and a representative set is shown in Figure 18B.  As pH lowers, the FITC fluorescence   
decreases along with concomitant increase of the QD fluorescence; the trend is 
essentially the same as in Figure 17C.  The fluorescence spectra were analyzed across 
multiple regions of interest (n ≥ 15), and the average A/D ratios are plotted as shown in 
Figure 18C.  The fluorescence spectra of the same QD-FITC conjugates assembled with 
JB858 were also measured in the same DPBS buffers as a control and the A/D ratios were 
compared (Figure 18D).  As observed in the cellular images, the FRET ratios measured in 
the extracellular environments correlate to an increase in the pH and can be potentially 
used to monitor changes in extracellular pH. To investigate the potential for the QD-FITC 
system to identify the extracellular pH, a series of unknowns were analyzed. In a blind    




Figure 17:464 nm QD-FITC Sensor Efficacy. 
                 
Figure 18. 464 nm QD-FITC Sensor Efficacy. (A) Representative images 
of the QD-FITC conjugates labeled using the membrane-localization peptide 
JB858 on COS-1 cells at the denoted pH levels. The images depict the spectral 
output from 440-625 nm in wavelength. The scale bar is 50 µm. (B) 
Superimposed pH-dependent fluorescence spectra of the QD-FITC conjugates 
with self-assembled JB858 bound on cellular membranes. (C) Plot of the 
acceptor peak intensity (A) / donor peak intensity (D) of the QD-FITC 
conjugates with self-assembled JB858 as a function of pH while bound on 
cellular membranes. From the cell images at each pH, the QD and FITC peak 
intensities were extracted from the spectral data of at least 15 individual ROI's, 
and the FRET ratio was averaged. (D) Normalized A/D comparing the 
responsiveness of the QD-FITC conjugates measured in DPBS on a TECAN 




labeled with A/B/C. Cells were labeled with the QD:FITC sensing system in the same 
manner as performed for the titration assay. Each of the unknown solutions were 
introduced to the cells, washed 2 times, and allowed to incubate in the unknown pH 
buffer for 15 minutes. Directly before imaging, the unknown buffer solution was replaced 
another 2 times to ensure that the final pH encountering the QD-FITC system was that of 
the unknown buffer. Images were taken and multiple ROIs were analyzed to determine 
the average A/D for each of the unknown pH’s, this value is noted as the measured pH 
(Figure 19). Using the titration curve, the measured values of the unknown pHs were 
calculated and compared to the expected unknown values and found to be within 3% of 
the values expected using a pH meter.    
Figure 18: Unknown pH Analysis. 
Figure 19. (A) Representative images of the QD-FITC conjugates labeled using the 
membrane-localization peptide JB858 on COS-1 cells at 3 unknown pH’s. The 
images depict the spectral output from 440-625 nm in wavelength. The scale bar is 
50 µm. From the cell images at each pH, the QD and FITC peak intensities were 
extracted from the spectral data of at least 10 individual ROI's, and the A/D ratio 
was averaged. Using the A/D standard curve for the QD-FITC constructs, the 
unknown pH’s were interpolated. The expected values and relative error for each 




We do note that the FRET ratio changes measured in the extracellular 
environment are not of the same magnitude as those measured in buffer solutions, 
although the response function is essentially the same as shown by the normalized data in 
Figure 15D.  We have previously demonstrated that conjugation of His-tagged 
biomolecules onto QD surfaces often increases fluorescence intensity of the QDs; this 
enhancement has been explained as passivation of the QD surface trap states by 
coordination of the oligohistidine 75, 160.  Despite the use of the same QD-FITC 
conjugates assembled with JB858 as control to cancel out the possible QD fluorescence 
enhancement promoted by the oligohistidine binding on the QD surfaces, the FRET ratios 
measured in the extracellular environments were still lower than those of the control 
samples at higher pHs.  One possible reason under the present experimental conditions is 
self-quenching of FITC in the cellular membranous environments.  It has been reported 
that fluorescein and other dyes aggregate in cellular membranes or vesicles and form 
nonfluorescent dimers 161-163.  Energy transfer from monomer to the nonfluorescent dimer 
can lead to significant fluorescence quenching.  Nevertheless, with careful calibration, the 




Few studies focus on the design of extracellular pH sensors, with the majority of 
systems designed to monitor pH focusing on the intracellular endolysosomal pathway. 
Sensors that have been implemented for extracellular pH sensing rely on fluorescent 




and physical degradation, low QYs and susceptibility to photobleaching. QDs are ideal 
for overcoming many of these limitations given their superior optical properties, and 
specifically a new range of biocompatible blue-emitting QDs produced at NRL can 
provide a scaffold for extracellular pH sensing. Capitalizing on the pH-responsive nature 
of FITC and the tunable emission of the blue-emitting QDs, 464 nm emitting QDs were 
conjugated with FITC to produce a FRET-based pH sensor. This sensor was further 
colocalized to the exofacial leaflet of the cellular membrane in cultured cells and 
produced a robust pH sensor with a high degree of accuracy. This sensing design has the 
potential to be used in tumor monitoring and other instances where the pH of the 





Chapter 5: Conclusions  
Conclusions Overview 
Producing an effective theranostic agent requires the careful consideration of 
many components, from the choice of parts to assembly of the system and the possible 
methods of cargo actuation, all while necessitating the ability to monitor what is 
happening in real-time. This project has focused on expanding our understanding of what 
is required to produce effective nanoscale theranostic systems. In order to build the 
effective ‘toolbox’ we examined multiple areas of interest including the surface 
chemistry of the NP scaffold used for construct design, the method of complex 
conjugation, and the intracellular location of assembly. We subsequently used the 
components of this ‘toolbox’ in the design of potential intracellular sensors and cargo 
actuation modalities. For all of these studies, we focused on the use of a proto-typical 
hard NP, namely - semiconductor quantum dot (QDs) as its optical properties afford easy 
monitoring potential. 
 First, in Chapter 2, we examined the efficacy of a FRET-based QD donor with 
mCherry used as an acceptor to determine the dependence of the chemistry and size of 
the capping ligand used to produce biocompatible QDs on the complex’s FRET 
efficiency (Figure 3). Additionally, the location of the final FRET construct inside the 
cells was analyzed for energy transfer efficiency optimization. To accomplish this 
analysis, cells were transfected with His6-tagged mCherry proteins present in either the 
cytosol or appended to the inner leaflet of the cellular membrane. Cells expressing the 
proteins were then microinjected with QDs capped with a range of capping ligands, and 




capping-ligand at both expression localizations). The capping ligand used clearly needs to 
be balanced between the passivation of the QD surface for biocompatibility while still 
allowing for the acceptor protein to be close enough to the donor QD. As discussed in the 
Introduction, the relationship between FRET efficiency and donor-acceptor distance is 
dependent on an inverse 6th factor, so a few nanometers in size difference can 
dramatically lower the efficiency13. The two longer capping ligands, DHLA-PEG750-OMe 
and DHLA-PEG600-NTA have estimated end-to-end sizes larger than 6 nm which is over 
three times the size of the small CL4 capping ligand (~1.8 nm)107. Coordination between 
the acceptor mCherry proteins and the QDs also varied for the capping ligand used, with 
the assembly driven by metal-affinity coordination for the PEG750-OMe and CL4 capping 
ligands compared to Ni2+-NTA assembly for the PEG600-NTA ligand. All of these factors 
contributed to our findings that the smallest, zwitterionic capping ligand CL4 produced 
the most efficient intracellular FRET both when associated to a cytosolically-expressed 
mCherry protein and to a transmembrane-appended mCherry. FRET efficiency produced 
by the complexed systems was also higher for the cytosolically-localized mCherry when 
compared to the transmembrane mCherry, which we attribute to the increased number of 
mCherry produced for cytosolic transfection and the steric hindrance caused by 
membrane-tethering the mCherry96. By closely examining the components of surface 
chemistry and protein localization, we have shown that we can assemble efficient FRET 
sensors intracellularly, as opposed to introducing a pre-fabricated construct to the cellular 
environment. This directly suggests that such theranostic devices can utilize some of the 
cellular machinery already in place as part of its function. The capping ligand used for the 




balance the necessity for stable colloidal QDs with the greatest FRET potential for 
visualization. Greater understanding of these individual components helps broaden the 
range of potential nanoparticle-based applications, be that for monitoring intracellular 
processes or the implementation of theranostic delivery agents. 
Second, in Chapter 3, we used the knowledge gained in the first aim to produce a 
novel intracellular actuation modality. Instead of relying on triggered delivery using 
conventional approaches like a change in the localized environment around the NP 
surface (e.g. pH 21, REDOX 23) or external application of a power source (e.g. ultrasound 
27, magnetism 24), we decided to explore a new mechanism for triggering cargo release - 
the addition of an inert secondary triggering molecule. Again, using QDs capped with 
CL4 capping ligands as our NP scaffold, we conjugated a carrier protein to the surface 
called maltose binding protein (MBP). Within the binding pocket, a maltose analog -
cyclodextrin (CD) acted as the carrier for both a dye (TF3) and a drug (DOX), each 
chosen to facilitate a visualizable FRET response after release (Figure 4). Once within the 
cytosol, actuation of the cargo occurred specifically in response to external delivery of 
maltose. We showed that the constructs functioned intracellularly, and responded in a 
visualizable manner to increasing addition of maltose extracellularly. This response 
tracked with both increased time and increasing maltose delivery, and the process 
occurred relatively quickly (<10 minutes) after maltose stimulation. This triggering 
mechanism using an innocuous secondary molecule is directly relevant to theranostics as 
it opens a new area for potential actuation methods that is more specific than passive 
delivery and does not have some of the limitations of other active triggering modalities. 




delivery, be that in the endosomal pathway or in the cytosol, and extracellularly triggered 
systems require for the targeted site to be known and application of the external power 
source (light 25-26, magnetism 24) can damage the surrounding tissue and have issues with 
depth penetration58. 
The actuation modality described in this dissertation is not reliant on location for 
release and has the potential to be targeted to specific cells through the addition of 
peptides or other targeting moieties. Using the sugar molecule maltose, in this example, 
means that there will be few systemic side effects given that maltose is consumed readily 
as it is the carbon source for bread and beer production and can be easily removed from 
the diet. Although we have proven that this type of actuation modality is a viable release 
mechanism, there are many hurdles still to overcome in implementing such a system. 
These include the long-term stability of the actuatable conjugate to ensure a low amount 
of cargo ‘leaking’ with effective targeting concentrations, the need to target the construct 
to a specific area within the body to ensure correct targeting, and the necessary dosing for 
both the NP complex and the secondary triggering molecule. Additionally, the use of the 
His6 tag could produce severe immune reactions if the MBP dissociates from the QD 
surface, and if the treatment required multiple doses of the NP complex. Shortening the 
histidine tag would overcome these issues, and we have previously shown that His5  tags 
can still efficiently coordinate to the QD surface108.  This actuation system utilizes the 
tools we’ve delineated in Chapter 2, showing one of the potential application possibilities 
that can be produced from our components.  
Finally, in Chapter 4, we used that same toolbox to tackle a difficult sensing 




of interest given the lowering in pH that occurs in tumor microenvironments. With this 
area changing from a normal pH of around 7.5 to as low as 5, a system that could 
effectively monitor the extracellular environment would be of benefit to researchers 95. 
Again, using the QD as a central scaffold, pH-responsive FITC molecules were appended 
to the surface and the whole complex was coordinated to the exofacial leaflet of the 
cellular membrane through the use of the peptide JB858 (Figure 5). The QDs utilized in 
this design are unique, however, in that they were specifically designed to be stable and 
emit in the blue range of wavelengths. Commonly used QDs have a CdSe core that is 
difficult to stabilize at the extremely small sizes required for emission below 500 nm, and 
addition of the protective ZnS shell shifts the emission wavelength further to the red 145. 
To overcome this, a Zn-doped CdS core was produced where the Zn was ratiometrically 
increased during synthesis, displacing the Cd and producing larger, and more stable, 
blue-emitting QDs. These new QDs were ideal as a FRET donor for FITC, and we 
showed in Chapter 4 that this FRET pair could quantifiably measure localized pH around 
the cellular membrane. Additionally, the system was robust enough to accurately 
determine ‘unknown’ pH values within 3% of the experimental value. This promising 
system could be used to image the pH change in the tumor microenvironment over time. 
Implementing such a system in a tumor model would require careful optimization of the 
delivery method, including timing, peptide ratio and sensor concentration, which could be 
made easier by the enhanced permeability and retention (EPR) effect that occurs in many 
tumor sites 136. Other considerations for real-time imaging in tissue would have to take 
into account the depth of imaging required (which can be increased through the use of 




curve of the sensor and the long-term localization of the sensor in tissue samples. This 
effective sensing technique was built using the understanding gained through analysis of 
available nanoscale tools that have the potential to be applied to numerous systems.   
This dissertation specifically contributed to our understanding of what is required 
for QD donors and FRET-based monitoring for use in nanoscale cellular sensing systems. 
The first aim of this dissertation specifically showed how critical the QD capping ligand 
is for both intracellular stability and the QD’s ability to assembly to acceptor proteins 
intracellularly. Additionally, we showed how it is possible to assemble FRET constructs 
to specific locations within the cell by modifying the location of the expressed acceptor 
protein. This research expanded the possibilities for implementing intracellular 
monitoring systems by reducing the number of components that need to be synthesized 
outside the cell and allowing for targeting to be incorporated into the acceptor protein 
instead of through the use of other targeting modalities that would take up precious space 
on the QD surface and reduce the overall FRET efficiency of the designed system. The 
second aim used the information learned from the first to successfully interrogate a novel 
method for cargo actuation that could be monitored using the same QD donor and FRET-
based monitoring. This type of extracellularly- triggered release of cargo has not been 
shown previously and is unique in that it does not rely on 1) achieving a specified 
location within the cell to trigger release as is required for active- intracellular actuation 
or 2) the knowledge of the location of the targeted treatment location as is required for 
current active- extracellularly triggered actuation. Instead, cargo release can occur 
wherever the location is simply by systemically delivering the innocuous triggering 




the growing field of theranostic systems. Finally, our final aim again used the same QD 
donor scaffold and FRET-based monitoring components to try to target an under-served 
area of tumor research by designing a new extracellular pH sensor. Using a new range of 
biologically stable, blue-emitting QDs and a proprietary extracellular labeling peptide, we 
capitalized on the inherent responsiveness of FITC to its localized pH environment as the 
FRTE acceptor molecule to produce the extracellular pH sensor. This system is one of 
very few sensors that monitor the extracellular pH and is the only one that utilizes this 
FRET-based method of sensing, which increases the possible tools available for cancer 
researchers for use in studying tumor microenvironments.  
Overall, we hope this work has displayed the incredible potential NPs provide for 
the design and implementation of sensing and actuation complexes. This is a difficult and 
complicated process and increasing the available methods for monitoring intracellular 
processes or the types of specified triggering for drug delivery can only help facilitate 
future breakthroughs.  
 
Future Directions 
 Each of the specific aims in this dissertation can be built upon to further advance 
the design of nanoscale theranostic agents. From Chapter 2, we produced the building 
blocks for potential intracellular sensors that can be complexed directly in the cell. Using 
QDs in these systems has numerous benefits, including their large 2 photon cross section 
164, their ability to act as a good FRET donor, their tunable emission for a range of 
acceptor molecules for optimum FRET efficiency, and that multiple acceptors can be 




one of the numerous GFP analogs could be used to produce a wide range of visualizable 
FRET pairs within the cell. Many labs are modifying these proteins to have even better 
photophysical properties, like the protein mScarlet, which emits in the same range as 
mCherry but has superior optical properties (QY ~70% compared to mCherry QY at 
~20%) 165. These proteins could be used to build even more efficient intracellular FRET 
complexes. Possible future avenues for study using these FRET complexes include the 
addition of cleavable regions between the histidine tag and the acceptor protein to assess 
intracellular enzyme activity. Once cleaved, the acceptor protein would no longer 
associate with the QD surface and the FRET efficiency of the system would change. This 
could be applied to numerous intracellular signaling pathways that rely on enzymatic 
activity to induce cellular responses. One such process is the apoptotic pathway, which 
activates enzymes called caspases in a signaling cascade to induce cellular death 166. 
Other possible intracellular responses include reactions to hormone stimulation like 
insulin 167 or kinase signaling pathways 168 that could be monitored intracellularly, 
comparing normal function to drug inhibition or stimulation. There are a wide range of 
processes that could be examined more closely by implementing such a FRET-based 
intracellular complex.    
Future work with the actuation modality from Chapter 3 would need to look at the 
longer-term stability of the structure in a cellular environment. We looked at the system 
for up to 6 hours intracellularly but for specified delivery the assembly would need to be 
studied over longer delivery periods. This stability would be critical for delivery to 
targets within the body, as it would take time for the delivered complex to accumulate in 




the HBSS used in this dissertation. In addition to the long-term stability the binding 
kinetics of the CD-TF3/DOX to the MBP while in the presence of other sugars and 
glycoproteins and glycolipids that would be present on the exofacial leaflet of cellular 
membranes should be examined as this could cause unwanted displacement of the cargo. 
In addition to determining the stability, a wide array of methods could be examined to 
target the complex to the desired cellular location. Incorporation of internalization 
modalities like the HIV derived TAT peptide or the use of JB858 or it’s internalization 
analog JB577 could introduce the complex to different areas of the cells and would need 
to be studied for the amount of peptide to MBP required for efficient targeting. If specific 
locations within the body were to be targeted, antibodies or molecules could also be 
associated with the QD surface and would need to undergo the same analysis as the 
intracellular targeting peptide to maximize cargo capacity and targeting efficiency. The 
final aspect that must be examined to determine the potential for this system to be 
effectively implemented in vivo is the determination of how maltose will be administered 
to stimulate release. If injected, the amount of maltose that enters the bloodstream would 
have to be discerned and if injected, the amount and circulation time of maltose would 
need to be studied to determine what doses the targeted locations received. For both of 
these delivery methods, it should be stated that an extremely large amount of maltose 
could cause issues like insulin disruption and glycemic shock and should be taken into 
consideration.  
To apply this complex to a larger range of diseases, a wider range of delivery 
cargos could be examined for the system’s efficacy based on cargo size. It would be 




that would be too unwieldy. This could increase the application potential for this cargo 
system to treat diseases other than cancer. Finally, the binding kinetics of the MBP could 
also be modified to be more or less responsive to the added maltose, which could provide 
slower delivery methods compared to the less than 10-minute release times shown in this 
research 169. This could be ideal as MBP could interact with the aforementioned 
glycoproteins and glycolipids, and so modifying the protein to be more specified to the 
cargo and displacement molecule could increase the delivery efficacy.  Alternative carrier 
proteins could be studied as well, with periplasmic binding proteins being specific for a 
range of molecules (various sugars 170, amino acids 171, metals 172-173 and even vitamins 
174) or the use of DNA aptamers designed to release in response to a delivered molecule 
175. This could be ideal in cancerous cells that have a high number of multiple drug 
resistance (MDR) pumps present in their cytoplasm, and so a slower rate of delivery 
would prevent loss of drug 176. We believe that this novel actuation system holds much 
potential for future directions in theranostic agents, providing a new way for specified 
drug release and delivery intracellularly from just the addition of an extracellular trigger 
– namely an innocuous nutrient. 
Finally, there are future directions that should be explored using our pH sensor 
from Chapter 4. First, the system should be introduced to cancerous cell lines to 
determine if those cells produce an acidic local environment around the cells, and then 
secondarily used to label actual tumor sites to measure their localized pH in vivo. 
Additionally, the ability of the system to label a three-dimensional tumor would need to 
be investigated. As one of the key features of tumor development is the loss of sufficient 




examined for both cultured tumor models and physical tumors in vivo. One interesting 
avenue of research could be to monitor non-tumor sites and determine if a change can be 
discerned in the pH around cells. If there is a pH change, could it occur before cancerous 
mutations are discovered - possibly providing a first warning sign for tumor models. 
Additionally, this sensor could eventually be coupled to therapeutic delivery. By varying 
the number of FITC per QD, surface area on the QD could be freed to carry cargo in 
addition to the sensing functionality. To produce a triggered release, acid-labile linkages 
could be used between the histidine tag and the drug analog 177. As the pH lowers around 
the cancerous cells, the sensing function would report on the localized conditions and the 
drug would be released for a therapeutic effect - producing another theranostic, 
multifunctional agent. The possibilities for drug delivery are widespread, but one 
promising option is doxorubicin, as it would allow for a secondary imaging possibility 
once it reached the nucleus.  
This dissertation has attempted to broaden the available methods for the design of 
theranostic agents. Each of the specific aims worked to introduce new techniques that can 
be further applied to future delivery modalities and sensing systems. As we become more 
and more fluent in the production of new hybrid bio-nano materials and their use in new 

















Figure A 2: Representative images and data from FRET bleaching experiments. 
Figure A1: Schematic of synthesized βCD-DOX.  
Figure A2: Representative images and data from FRET bleaching experiments. 
COS-1 cells injected with QD-MBP-βCD-TF3 and imaged spectrally from 430nm – 
730 nm. Red highlighted region on interest was bleached using a 561 nm laser to 
remove the TF3 fluorescence. Using the spectral profiles from before and after 
bleaching and Equation 3, the FRET efficiency was calculated over n=23 cells. Data 






Figure A 4: Representative image and data from FLIM analysis. 
 
Figure A4: Representative image and data from FLIM analysis. COS-1 cells injected 
with QD alone, QD-MBP-βCD-TF3, and QD-MBP-βCD-DOX were imaged using a FLIM 
microscope. Representative image shows QDs alone and the average counts captured over 
time for the injected cells. Table shows lifetime data collected for both of the QD constructs 
before and after 30 mM maltose addition compared to that shown by QDs alone.  
Figure A 5: βCD-DOX and free DOX delivery comparison. 
 
Figure A5: βCD-DOX and free DOX delivery comparison. COS-1 cells treated for 2 
hours with 10 M βCD-DOX or free DOX and imaged for DOX localization.   
Figure A 3: Rate equation used for maltose delivery analysis. 
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